Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Obs Exp SIR 95% CI Exp SIR 95% CI Bladder, Urinary Melanoma of Skin 2 Male 4 4.6 nc (nc-nc) Male 3.2 (nc-nc) nc Female 0 1.4 nc (nc-nc) Female 5 2.4 207.6 (66.9 - 484.6)**Brain and Other Nervous System** Multiple Myeloma Male 0 1.1 nc (nc-nc) Male 0 8.0 nc (nc-nc) Female 8.0 Female 0 0.4 1 nc (nc-nc) nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 Male Male 0.1 (nc-nc) 4 2.7 (nc-nc) nc nc 25 18.8 Female 0 Female 132.8 (85.9-196.1)1.9 nc (nc-nc) Cervix Uteri Oral Cavity and Pharynx Male 5 2.3 215.3 (69.4-502.4)Female 1 0.9 Female 0 8.0 nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary 7.3 Male 4 nc (nc-nc) 4 Female 5.2 nc (nc-nc) Female 0 1.9 nc (nc-nc) **Esophagus Pancreas** Male 0 Male 1 1.4 nc (nc-nc) 1.5 nc (nc-nc) Female 0 0.3 (nc-nc) Female 0 1.1 nc (nc-nc) nc Hodgkin Lymphoma **Prostate** 1 20 Male 0.4 nc (nc-nc) Male 21.6 92.7 (56.6-143.2)Female 0 0.3 nc (nc-nc) Kidney and Renal Pelvis Stomach Male 1 2.5 Male 1 1.1 nc (nc-nc) nc (nc-nc) 1.2 0 0.5 Female 1 (nc-nc) Female (nc-nc) nc nc Larynx Testis Male 0 0.9 (nc-nc) Male 0 0.6 (nc-nc) nc nc Female 0 0.2 nc (nc-nc) Leukemia Thyroid 2 2 8.0 Male 1.6 nc (nc-nc) Male nc (nc-nc) Female 1 1.0 Female 1 2.4 (nc-nc) nc (nc-nc) nc Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 1.3 (nc-nc) nc Female 0 3 0.3 nc (nc-nc) **Female** 4.1 (nc-nc) nc **Lung and Bronchus** All Sites / Types

• Obs = observed case count; Exp = expected case count;

9.3

7.1

5

1

Male

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(17.4-126.0)

(nc-nc)

Shading indicates the statistical significance of the SIR at 95% level of probability;

54.0

nc

• nc = The SIR and 95% CI were not calculated when Obs < 5;

55

47

Male

Female

79.0

82.8

(59.5-102.9)

(60.8-110.1)

69.6

56.8

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр 95% CI Obs SIR 95% CI SIR Exp Bladder, Urinary Melanoma of Skin 9 79.1 11 13.9 (39.4-141.5)Male 7.9 113.4 (51.7-215.3)Male 3 7 Female 4.7 nc (nc-nc) Female 6.1 114.2 (45.7-235.3)**Brain and Other Nervous System** Multiple Myeloma 5 2.5 199.2 5 2.1 235.0 Male (64.2-465.0)Male (75.7-548.3)2 2.0 Female 0 1.4 Female nc (nc-nc) (nc-nc) nc Non-Hodgkin Lymphoma **Breast** Male 1 0.4 (nc-nc) Male 4 7.1 (nc-nc) nc nc 39 Female 45.7 85.4 (60.7-116.7)Female 2 6.1 (nc-nc) nc Cervix Uteri Oral Cavity and Pharynx 6 (44.9 - 267.7)4.9 123.0 Male 2 2.0 2 2.2 Female (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 19 20.2 94.1 (56.6-147.0) Female 16 17.7 90.5 (51.7-146.9)**Female** 6 4.9 121.9 (44.5-265.4)**Esophagus Pancreas** 9 261.4 4 3.4 (119.3-496.3)4.0 Male Male nc (nc-nc) 0.9 Female 8 3.9 Female 0 nc (nc-nc) 206.0 (88.7-405.9)Hodgkin Lymphoma **Prostate** 0 1.0 Male 52 50.3 103.3 Male nc (nc-nc) (77.2-135.5)Female 0 8.0 nc (nc-nc) Kidney and Renal Pelvis Stomach Male 8 6.0 134.3 (57.8-264.6)Male 5 3.4 147.0 (47.4 - 343.1)Female 5 3.6 139.3 (44.9 - 325.0)Female 3 1.8 nc (nc-nc) Larynx **Testis** 1 2 2.1 1.6 Male (nc-nc) Male (nc-nc) nc nc 0 0.6 Female (nc-nc) nc **Leukemia Thyroid** (49.6-295.4) 4.4 135.7 2 1.7 Male 6 Male (nc-nc) nc Female 2 3.2 nc (nc-nc) Female 7 5.3 131.0 (52.5-269.9)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS 2 Male 2.9 nc (nc-nc) Female 1 0.9 Female 6 9.7 62.0 (22.6-134.9)nc (nc-nc) Lung and Bronchus All Sites / Types 29 25.8 189 179.1 105.5 Male 112.6 (75.4-161.7)Male (91.0-121.7)Female 24 22.8 105.2 (67.4-156.6) Female 150 158.6 94.6 (80.0-111.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

| | <u>Obs</u> | Ехр | SIR | 95% CI | With Standardized incidence Rat | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI |
|-----------------------|-------------|-----------|-------|--------------|---------------------------------|------------|------------|-------|--------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| Brain and Other Nerv | ous Syste | <u>em</u> | | | Multiple Myeloma | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 8.0 | nc | (nc-nc) |
| Female | 10 | 5.4 | 186.6 | (89.3-343.2) | Female | 0 | 0.7 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | | | | | |
| Female | 1 | 1.9 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 3 | 6.0 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>lvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 0.5 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| Liver and Intrahepati | c Bile Duc | | | | Uteri Corpus and Uterus, I | <u>NOS</u> | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 1 | 2.8 | nc | (nc-nc) | Male | 13 | 19.9 | 65.4 | (34.8-111.8) |
| Female | 0 | 2.4 | nc | (nc-nc) | Female | 19 | 17.8 | 106.9 | (64.3-166.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | min Standardized meldence it | <u>Obs</u> | <u>Ехр</u> | SIR | <u>95% CI</u> |
|----------------------|--------------|-------------|-------|---------------|------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 2 | 8.9 | nc | (nc-nc) | Male | 2 | 6.3 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) | Female | 4 | 5.5 | nc | (nc-nc) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 6 | 2.2 | 274.6 | (100.3-597.8) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) | Female | 2 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphon | <u>na</u> | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 5 | 5.5 | 91.7 | (29.5-213.9) |
| Female | 41 | 37.3 | 110.0 | (78.9-149.2) | Female | 6 | 4.4 | 137.1 | (50.1-298.5) |
| Cervix Uteri | | | | | Oral Cavity and Pharyn | <u>x</u> | | | |
| | | | | | Male | 6 | 4.1 | 146.2 | (53.4-318.3) |
| Female | 2 | 2.0 | nc | (nc-nc) | Female | 2 | 1.7 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 13 | 13.9 | 93.7 | (49.9-160.3) | | | | | |
| Female | 13 | 12.4 | 104.7 | (55.7-179.1) | Female | 3 | 3.9 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 1 | 2.5 | nc | (nc-nc) | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 6 | 2.6 | 229.1 | (83.7-498.6) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 33 | 36.1 | 91.3 | (62.8-128.2) |
| Female | 0 | 8.0 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 3 | 4.7 | nc | (nc-nc) | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 3.3 | nc | (nc-nc) | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) | Female | 4 | 5.5 | nc | (nc-nc) |
| Liver and Intrahepat | tic Bile Du | <u>icts</u> | | | Uteri Corpus and Uteru | s, NOS | | | |
| Male | 1 | 2.3 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 7 | 7.5 | 92.8 | (37.2-191.2) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 25 | 16.9 | 148.3 | (96.0-218.9) | Male | 122 | 128.9 | 94.7 | (78.6-113.0) |
| Female | 21 | 14.6 | 143.7 | (88.9-219.7) | Female | 133 | 121.2 | 109.8 | (91.9-130.1) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | with Standardized incidence | Obs | <u>Ехр</u> | SIR | <u>95% CI</u> |
|---------------------|--------------|-------------|-------|---------------|-----------------------------|-----------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 23 | 16.9 | 135.9 | (86.1-204.0) | Male | 11 | 8.1 | 136.3 | (68.0-243.9) |
| Female | 11 | 6.0 | 183.4 | (91.4-328.2) | Female | 8 | 5.6 | 142.1 | (61.2-279.9) |
| Brain and Other Ner | rvous Sys | stem_ | | | Multiple Myeloma | | | | |
| Male | 3 | 2.2 | nc | (nc-nc) | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) | Female | 0 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 2 | 0.4 | nc | (nc-nc) | Male | 8 | 7.5 | 107.1 | (46.1-211.0) |
| Female | 64 | 45.9 | 139.3 | (107.3-177.9) | Female | 3 | 7.1 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) | Female | 1 | 2.5 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 27 | 23.3 | 115.7 | (76.2-168.4) | | | | | |
| Female | 19 | 23.1 | 82.1 | (49.4-128.2) | Female | 10 | 5.2 | 194.1 | (92.9-356.9) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 6 | 3.8 | 156.3 | (57.1-340.1) | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 7 | 5.1 | 137.0 | (54.9-282.4) |
| Hodgkin Lymphoma | <u>a</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 75 | 56.6 | 132.6 | (104.3-166.2) |
| Female | 2 | 0.5 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 12 | 6.1 | 195.8 | (101.0-342.0) | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 4.0 | nc | (nc-nc) | Female | 1 | 2.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 3 | 2.3 | nc | (nc-nc) | Male | 1 | 8.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 4.6 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 6 | 3.6 | 164.6 | (60.1-358.2) | Female | 3 | 3.7 | nc | (nc-nc) |
| Liver and Intrahepa | tic Bile Du | <u>ucts</u> | | | Uteri Corpus and Uteri | us, NOS | | | |
| Male | 2 | 2.9 | nc | (nc-nc) | | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 12 | 10.0 | 119.8 | (61.8-209.3) |
| Lung and Bronchus | <u> </u> | | | | All Sites / Types | | | | |
| Male | 19 | 30.3 | 62.6 | (37.7-97.8) | Male | 212 | 199.2 | 106.4 | (92.6-121.8) |
| Female | 21 | 27.2 | 77.1 | (47.7-117.8) | Female | 190 | 175.4 | 108.3 | (93.5-124.9) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | With Standardized incidence | <u>Obs</u> | <u>Ехр</u> | <u>SIR</u> | <u>95% CI</u> |
|---------------------|---------------|-------------|-------|--------------|-----------------------------|------------|------------|------------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 30 | 34.9 | 86.0 | (58.0-122.7) | Male | 21 | 22.0 | 95.5 | (59.1-145.9) |
| Female | 14 | 14.0 | 100.2 | (54.8-168.2) | Female | 15 | 19.0 | 79.1 | (44.2-130.4) |
| Brain and Other No | ervous Sys | stem_ | | | Multiple Myeloma | | | | |
| Male | 4 | 7.1 | nc | (nc-nc) | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 3 | 6.0 | nc | (nc-nc) | Female | 3 | 4.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | <u>na</u> | | | |
| Male | 2 | 1.0 | nc | (nc-nc) | Male | 22 | 19.2 | 114.7 | (71.9-173.7) |
| Female | 167 | 143.3 | 116.6 | (99.6-135.7) | Female | 21 | 18.2 | 115.2 | (71.3-176.1) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>ıx</u> | | | |
| | | | | | Male | 12 | 14.3 | 83.7 | (43.2-146.3) |
| Female | 4 | 6.2 | nc | (nc-nc) | Female | 4 | 6.8 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 54 | 52.7 | 102.5 | (77.0-133.8) | | | | | |
| Female | 63 | 53.1 | 118.7 | (91.2-151.8) | Female | 15 | 15.3 | 98.3 | (55.0-162.1) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 11 | 9.4 | 117.3 | (58.5-210.0) | Male | 9 | 10.5 | 85.5 | (39.0-162.3) |
| Female | 3 | 2.7 | nc | (nc-nc) | Female | 10 | 11.6 | 86.5 | (41.4-159.1) |
| Hodgkin Lymphom | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 3.0 | nc | (nc-nc) | Male | 159 | 143.9 | 110.5 | (94.0-129.1) |
| Female | 4 | 2.2 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 19 | 16.9 | 112.4 | (67.6-175.5) | Male | 4 | 8.6 | nc | (nc-nc) |
| Female | 11 | 10.8 | 101.4 | (50.6-181.5) | Female | 6 | 5.5 | 108.4 | (39.6-235.9) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 4 | 5.9 | nc | (nc-nc) | Male | 5 | 5.1 | 98.2 | (31.7-229.2) |
| Female | 0 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 16 | 11.7 | 137.2 | (78.4-222.9) | Male | 12 | 5.4 | 223.7 | (115.4-390.7) |
| Female | 15 | 9.6 | 155.6 | (87.0-256.7) | Female | 16 | 16.8 | 95.4 | (54.5-155.0) |
| Liver and Intrahepa | atic Bile D | <u>ucts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 8 | 8.1 | 98.8 | (42.5-194.7) | | | | | |
| Female | 2 | 2.9 | nc | (nc-nc) | Female | 32 | 31.1 | 102.9 | (70.4-145.2) |
| Lung and Bronchu | <u>IS</u> | | | | All Sites / Types | | | | |
| Male | 68 | 67.6 | 100.6 | (78.1-127.5) | Male | 500 | 487.1 | 102.7 | (93.9-112.1) |
| Female | 67 | 67.4 | 99.4 | (77.0-126.2) | Female | 503 | 485.3 | 103.6 | (94.8-113.1) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs 95% CI Obs SIR 95% CI Ехр SIR Exp Bladder, Urinary Melanoma of Skin 28 29.9 93.6 8 42.8 Male (62.2-135.3) 18.7 (18.4-84.2)Male Female 11 10.5 104.4 (52.1-186.9)Female 10 15.3 65.4 (31.3-120.3)**Brain and Other Nervous System** Multiple Myeloma 8 6.3 126.2 128.2 (46.8-279.1)Male (54.4-248.8)Male 6 4.7 Female 7 5.0 140.3 (56.2-289.0) Female 2 3.2 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 0 0.8 (nc-nc) Male 21 16.5 127.1 (78.7-194.3)nc Female 86 101.8 84.5 (67.6-104.3)Female 20 14.0 142.9 (87.3-220.7)Cervix Uteri Oral Cavity and Pharynx 17 10.9 156.5 (91.1-250.7)Male 5.1 215.5 (107.4 - 385.5)4 Female 11 Female 5.1 (nc-nc) nc Colon / Rectum Ovary Male 45 44.0 102.3 (74.6-136.9) 120.1 (88.9-158.8) **Female** 49 40.8 **Female** 10 11.1 90.4 (43.3-166.3)**Esophagus Pancreas** 9 7.5 201.2 15 (112.5-331.8)8.7 103.1 (47.1-195.8)Male Male 2.1 Female 5 Female 1 nc (nc-nc) 8.8 56.8 (18.3-132.5)Hodgkin Lymphoma **Prostate** 3 3.3 Male 90 109.5 82.2 Male nc (nc-nc) (66.1-101.1) Female 0 2.4 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 19 13.4 141.8 (85.4-221.5) Male 10 7.4 134.6 (64.4-247.6)Female 7 8.0 0.88 (35.3-181.3)Female 9 4.4 203.2 (92.7 - 385.7)Larynx **Testis** 12 260.2 (134.3-454.5)4.6 1 6.2 Male Male (nc-nc) nc 4 Female 1.2 (nc-nc) nc **Leukemia Thyroid** 9 10.6 85.1 Male (38.8-161.6)Male 4 4.7 (nc-nc) nc Female 8 8.1 99.3 (42.8-195.7)Female 14 14.3 97.7 (53.4-163.9) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS 206.3 Male 13 6.3 (109.7 - 352.8)Female 4 2.2 Female 22 103.9 (65.1-157.3)nc (nc-nc) 21.2 Lung and Bronchus All Sites / Types 399.8 55.4 102.8 (93.1-113.2) Male 64 115.6 (89.0-147.6) Male 411 Female 50 48.8 102.4 (76.0-135.0)Female 362 362.2 99.9 (89.9-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

| | Obs | <u>Ехр</u> | SIR | 95% CI | s, with Standardized incluence | Obs | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|-------------|----------|----------------|--------------------------------|----------|------------|----------|---|
| Bladder, Urinary | <u> </u> | =~F | <u> </u> | <u>7070 01</u> | Melanoma of Skin | <u> </u> | <u> </u> | <u>v</u> | 7076 01 |
| Male | 7 | 4.4 | 160.0 | (64.1-329.8) | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) | Female | 5 | 1.8 | 276.0 | (88.9-644.1) |
| Brain and Other Ner | | | | (, | Multiple Myeloma | | | | (====================================== |
| Male | 3 | 0.8 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) | Female | 2 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | ` , | Non-Hodgkin Lymphoma | | | | , , |
| | 0 | 0.1 | nc | (nc-nc) | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 18 | 13.7 | 131.7 | (78.0-208.2) | Female | 2 | 1.7 | nc | (nc-nc) |
| Cervix Uteri | | | | , | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 6.5 | 122.5 | (52.7-241.4) | - | | | | |
| Female | 5 | 4.9 | 102.6 | (33.1-239.4) | Female | 0 | 1.5 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 1.1 | nc | (nc-nc) | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 5 | 1.1 | 469.2 | (151.2-1094.9) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 16 | 17.5 | 91.3 | (52.2-148.3) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 2 | 2.0 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 1 | 1.6 | nc | (nc-nc) |
| Liver and Intrahepat | tic Bile Du | <u>ucts</u> | | | Uteri Corpus and Uterus, | NOS | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 3.0 | nc | (nc-nc) |
| Lung and Bronchus | <u>i</u> | | | | All Sites / Types | | | | |
| Male | 12 | 8.4 | 143.5 | (74.1-250.7) | Male | 65 | 59.3 | 109.6 | (84.6-139.7) |
| Female | 8 | 6.4 | 125.9 | (54.2-248.2) | Female | 54 | 45.7 | 118.1 | (88.7-154.2) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

| | <u>Obs</u> | | SIR | 95% CI | with Standardized incluence Ka | Obs | | SIR | <u>95% CI</u> |
|-----------------------|------------|------------|-------------|--------------|--------------------------------|------------|------------|-------------|---------------|
| Bladder, Urinary | 005 | <u>Exp</u> | <u> SIK</u> | 93% CI | Melanoma of Skin | <u>ODS</u> | <u>Exp</u> | <u> SIK</u> | 95% CI |
| Male | 1 | 1.4 | | (20, 20) | <u>Male</u> | 0 | 0.0 | | (no no) |
| | 1 | 1.4 | nc | (nc-nc) | | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| Brain and Other Nerv | • | | | , , | Multiple Myeloma | • | 0.0 | | , , |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 8.0 | nc | (nc-nc) |
| Female | 7 | 4.9 | 142.8 | (57.2-294.2) | Female | 1 | 0.6 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | Female | 2 | 0.5 | nc | (nc-nc) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 2 | 5.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | elvis | | | | <u>Stomach</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | , , |
| <u>Leukemia</u> | | | | , | <u>Thyroid</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| Liver and Intrahepati | | | | (112 113) | Uteri Corpus and Uterus, | | | | (112 112) |
| Male | 0 | 0.3 | nc | (nc-nc) | <u> </u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 2 | 1.0 | nc | (nc-nc) |
| Lung and Bronchus | J | 5.1 | 110 | (110 110) | All Sites / Types | - | 1.0 | .10 | (110 110) |
| Male | 3 | 2.7 | nc | (nc-nc) | Male | 11 | 19.5 | 56.4 | (28.1-100.9) |
| Female | 1 | 2.2 | nc | (nc-nc) | Female | 19 | 16.1 | 117.8 | (70.9-184.0) |
| гентате | ı | ۷.۷ | IIC | (116-116) | remale | 17 | 10.1 | 111.0 | (10.7-104.0) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs SIR 95% CI Obs SIR 95% CI Ехр Exp Bladder, Urinary Melanoma of Skin 2 Male 1.2 1 8.0 nc (nc-nc) Male nc (nc-nc) Female 1 0.4 nc (nc-nc) Female 2 0.6 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma Male 0 0.3 0 0.2 (nc-nc) nc (nc-nc) Male nc Female 0 0.2 Female 0 0.1 nc (nc-nc) (nc-nc) nc Non-Hodgkin Lymphoma **Breast** Male 0 0.0 (nc-nc) Male 0 0.7 (nc-nc) nc nc Female 4 4.6 (nc-nc) Female 0 0.5 (nc-nc) nc nc Oral Cavity and Pharynx Cervix Uteri 2 0.5 Male (nc-nc) nc 0 0.2 Female 0 0.2 Female (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary 1 1.9 Male nc (nc-nc) Female Female 0 1.4 1 0.5 (nc-nc) nc (nc-nc) nc **Esophagus** <u>Pancreas</u> 0 0 0.3 0.4 Male nc (nc-nc) Male nc (nc-nc) 0 Female 0 Female 0.1 nc (nc-nc) 0.3 (nc-nc) nc Hodgkin Lymphoma **Prostate** 5 Male 0 0.1 Male 5.2 95.8 (30.9-223.7)nc (nc-nc) Female 0 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach 0 Male 0 0.6 nc (nc-nc) Male 0.3 nc (nc-nc) Female 0 0.3 (nc-nc) Female 0 0.1 (nc-nc) nc nc Larynx **Testis** 0 0 0.2 Male 0.2 (nc-nc) Male (nc-nc) nc nc 0 Female 0.1 (nc-nc) nc **Leukemia Thyroid** 0 0.4 0 0.2 Male nc (nc-nc) Male nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 0 0.6 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0.3 1 nc (nc-nc) Female 0 0.1 Female 2 nc (nc-nc) 1.0 nc (nc-nc) Lung and Bronchus All Sites / Types 2 15 Male 2.4 nc (nc-nc) Male 17.7 84.6 (47.3-139.6)Female 2 1.9 nc (nc-nc) Female 13 14.7 88.4 (47.0-151.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs 95% CI Obs Ехр SIR 95% CI Exp SIR Bladder, Urinary Melanoma of Skin 64 68.4 93.5 (72.0-119.5)31 38.6 80.3 (54.6-114.0)Male Male 31 Female 27.1 114.3 (77.6-162.2)Female 29 32.4 89.6 (60.0-128.7)**Brain and Other Nervous System** Multiple Myeloma 12 12.0 100.1 (51.7-174.9)10 10.5 95.6 Male Male (45.8-175.9)Female 7 10.3 68.0 (27.2-140.0)Female 9 8.3 108.2 (49.4-205.4)Non-Hodgkin Lymphoma **Breast** 0 1.9 (nc-nc) Male 34 34.6 98.2 (68.0-137.2)Male nc Female 234 243.3 96.2 (84.2-109.3)Female 28 34.4 81.4 (54.0-117.6)Cervix Uteri Oral Cavity and Pharynx 24 23.8 100.7 (64.5-149.9)Male 9.9 60.6 12.3 Female 6 (22.1-132.0)Female 14 114.3 (62.4-191.7)Colon / Rectum Ovary Male 79 99.1 79.7 (63.1-99.3)Female **Female** 101 103.4 97.7 (79.6-118.7)23 26.7 86.2 (54.6-129.4)**Esophagus Pancreas** 14 17.0 82.6 (45.1-138.5)12 19.9 60.4 (31.2-105.5)Male Male Female Female 4 5.4 nc (nc-nc) 22 22.7 96.8 (60.6-146.5)**Prostate** Hodgkin Lymphoma 3 5.1 243 251.2 96.7 Male nc (nc-nc) Male (85.0-109.7) Female 3 4.1 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 24 29.2 82.3 (52.7-122.4)Male 25 16.7 149.9 (97.0-221.3)Female 16 19.8 8.08 (46.1-131.2)Female 11 11.0 100.3 (50.0-179.6)Larynx **Testis** 10 10.4 96.0 (45.9-176.5)6 8.2 73.5 (26.9-160.1)Male Male 2 Female 3.0 (nc-nc) nc **Leukemia Thyroid** 18 83.9 (49.7-132.6)2 8.4 Male 21.5 Male (nc-nc) nc Female 13 18.0 72.3 (38.5-123.6)Female 21 26.4 79.5 (49.2-121.5)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 16 13.9 114.9 (65.6-186.5)Female 7 5.4 129.1 Female 65 52.2 124.4 (96.0-158.6)(51.7-266.1)Lung and Bronchus All Sites / Types 127.5 102.0 883.0 93.7 (87.4-100.3) Male 130 (85.2-121.1)Male 827 Female 124 128.6 96.5 (80.2-115.0)Female 838 874.9 95.8 (89.4-102.5)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs SIR 95% CI Obs Ехр SIR 95% CI Exp Bladder, Urinary Melanoma of Skin Male 1 1 8.0 (nc-nc) 1.5 nc (nc-nc) Male nc 0 Female 0.5 nc (nc-nc) Female 1 0.6 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 0.2 0 0.2 (nc-nc) Male nc (nc-nc) Male nc Female 0 0.2 Female 0 0.1 (nc-nc) nc (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 0 Male 0.0 (nc-nc) Male 0 8.0 (nc-nc) nc nc Female 4 4.6 (nc-nc) Female 0 0.6 (nc-nc) nc nc Oral Cavity and Pharynx Cervix Uteri 0.5 Male 1 (nc-nc) nc Female 0 0.2 Female 0 0.2 (nc-nc) (nc-nc) nc nc Colon / Rectum Ovary Male 1 2.2 nc (nc-nc) 0 0.5 **Female** 1.8 (nc-nc) **Female** 0 (nc-nc) nc nc **Esophagus Pancreas** 0 0 0.4 0.5 Male nc (nc-nc) Male nc (nc-nc) Female 0 Female 1 0.1 nc (nc-nc) 0.4 nc (nc-nc) Hodgkin Lymphoma **Prostate** 7 Male 0 0.1 Male 5.9 119.3 (47.8-245.8)(nc-nc) nc Female 0 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 1 0.6 nc (nc-nc) Male 0 0.4 nc (nc-nc) Female 0 0.4 (nc-nc) Female 0 0.2 (nc-nc) nc nc Larynx Testis 0 Male 1 0.2 Male 0.1 (nc-nc) (nc-nc) nc nc Female 0 0.1 (nc-nc) nc **Leukemia Thyroid** 0 0.5 0 0.2 Male nc (nc-nc) Male nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 1 0.5 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 0.3 nc (nc-nc) Female 0 0.1 (nc-nc) Female 0 1.0 nc nc (nc-nc) Lung and Bronchus All Sites / Types 0 2.9 19.9 70.5 (38.5-118.3)Male (nc-nc) Male 14 nc Female 2 2.2 nc (nc-nc) Female 10 15.7 63.8 (30.5-117.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

| | <u>Obs</u> | Exp | SIR | 95% CI | With Standardized incidence Rat | <u>Obs</u> | <u>Ехр</u> | SIR | <u>95% CI</u> |
|-------------------------|-------------|------------|-------|--------------|---------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 4 | 2.2 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| Brain and Other Nerv | ous Syste | <u>em</u> | | | Multiple Myeloma | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.5 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 3.2 | nc | (nc-nc) | | | | | |
| Female | 5 | 2.8 | 176.7 | (56.9-412.4) | Female | 1 | 0.8 | nc | (nc-nc) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 7 | 9.2 | 76.4 | (30.6-157.5) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>lvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 2 | 1.0 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 1 | 8.0 | nc | (nc-nc) |
| Liver and Intrahepation | c Bile Duc | <u>ets</u> | | | Uteri Corpus and Uterus, I | <u>vos</u> | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 8 | 4.3 | 187.1 | (80.6-368.7) | Male | 30 | 29.9 | 100.3 | (67.7-143.2) |
| Female | 8 | 3.7 | 217.3 | (93.5-428.1) | Female | 29 | 25.6 | 113.3 | (75.8-162.7) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр SIR 95% CI Obs Ехр SIR 95% CI Bladder, Urinary Melanoma of Skin 90.3 13 14.4 (48.0-154.4)6 8.7 68.9 (25.2-150.0)Male Male 8 7 Female 6.1 131.2 (56.5-258.5)Female 7.7 90.6 (36.3-186.7)**Brain and Other Nervous System** Multiple Myeloma 4 (nc-nc) 3 2.3 (nc-nc) Male 2.8 nc Male nc Female 0 2.4 (nc-nc) Female 3 1.9 nc nc (nc-nc) Non-Hodgkin Lymphoma **Breast** 5 Male 0 0.4 (nc-nc) Male 7.7 64.9 (20.9-151.4)nc 7 Female 34 56.2 60.5 (41.9 - 84.5)Female 7.8 89.3 (35.8-184.0)Cervix Uteri Oral Cavity and Pharynx 7 5.4 130.7 Male (52.4-269.3)5 2.4 204.3 3 2.8 Female (65.9-476.9)Female (nc-nc) nc Colon / Rectum Ovary Male 31 21.2 146.1 (99.3-207.4)101.9 Female 9 Female 24 23.6 (65.3-151.6)6.1 146.8 (67.0-278.8)**Esophagus Pancreas** 5 1 4.2 3.7 136.6 (44.0-318.8)Male Male nc (nc-nc) 2 Female 5 5.1 Female 1.2 nc (nc-nc) 97.4 (31.4-227.3)Hodgkin Lymphoma **Prostate** 2 Male 1.3 41 54.2 75.6 nc (nc-nc) Male (54.3-102.6)Female 0 1.0 nc (nc-nc) Kidney and Renal Pelvis Stomach Male 6 6.5 92.4 (33.8-201.2)Male 3 3.6 (nc-nc) nc Female 6 4.5 133.9 (48.9 - 291.5)Female 2 2.5 (nc-nc) nc Larynx **Testis** 3 1 2.2 2.3 Male (nc-nc) Male (nc-nc) nc nc 1 Female 0.7 (nc-nc) nc **Leukemia Thyroid** 2 4.8 (nc-nc) 2.1 Male nc Male 1 nc (nc-nc) Female 6 4.2 143.3 (52.3-312.0) Female 5 6.6 75.8 (24.4-176.9)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 3 3.1 nc (nc-nc) Female 1 1.2 Female 6 11.9 50.6 (18.5-110.1)nc (nc-nc) **Lung and Bronchus** All Sites / Types 34 27.0 125.7 191.9 96.9 Male (87.1-175.7)Male 186 (83.5-111.9)

• Obs = observed case count; Exp = expected case count;

28.5

Female

25

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(56.8-129.6)

Shading indicates the statistical significance of the SIR at 95% level of probability;

87.8

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

174

200.6

86.7

(74.3-100.6)

Cohasset

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | , with Standardized incidence | <u>Obs</u> | <u>Ехр</u> | SIR | <u>95% CI</u> |
|----------------------------|--------------------|-------------|-------|--------------|-------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 13 | 8.7 | 149.1 | (79.3-255.0) | Male | 14 | 5.2 | 269.6 | (147.3-452.4) |
| Female | 4 | 3.3 | nc | (nc-nc) | Female | 15 | 4.2 | 358.2 | (200.3-590.8) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | <u>na</u> | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 6 | 4.6 | 131.0 | (47.8-285.1) |
| Female | 31 | 32.5 | 95.5 | (64.9-135.6) | Female | 2 | 4.2 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 12 | 13.0 | 92.4 | (47.7-161.5) | | | | | |
| Female | 15 | 12.4 | 121.2 | (67.8-200.0) | Female | 5 | 3.5 | 144.3 | (46.5-336.8) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 2.3 | nc | (nc-nc) | Male | 5 | 2.6 | 192.4 | (62.0-449.1) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 1 | 2.7 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>l</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 42 | 34.6 | 121.4 | (87.5-164.1) |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 7 | 4.0 | 173.7 | (69.6-357.8) | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) | Female | 0 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.4 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 2.8 | 177.8 | (57.3-414.8) | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) | Female | 6 | 3.6 | 167.7 | (61.2-364.9) |
| Liver and Intrahepat | <u>tic Bile Du</u> | <u>icts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 1 | 1.9 | nc | (nc-nc) | | | | | |
| Female | 2 | 0.7 | nc | (nc-nc) | Female | 9 | 7.0 | 128.7 | (58.7-244.4) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 17 | 16.6 | 102.3 | (59.6-163.8) | Male | 151 | 117.7 | 128.3 | (108.6-150.4) |
| Female | 10 | 15.7 | 63.7 | (30.5-117.2) | Female | 114 | 110.9 | 102.8 | (84.8-123.5) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | with Standardized incidence Ru | Obs | <u>Ехр</u> | SIR | <u>95% CI</u> |
|-----------------------|-------------|------------|-------|--------------|--------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 4 | 2.2 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| Brain and Other Nerv | ous Syste | <u>em</u> | | | Multiple Myeloma | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 9 | 6.7 | 134.4 | (61.3-255.2) | Female | 0 | 0.8 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 3.2 | nc | (nc-nc) | | | | | |
| Female | 1 | 2.3 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 3 | 0.5 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 6 | 8.4 | 71.2 | (26.0-155.0) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>lvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| Liver and Intrahepati | c Bile Duc | <u>cts</u> | | | Uteri Corpus and Uterus, | <u>NOS</u> | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 2 | 1.4 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 4 | 4.1 | nc | (nc-nc) | Male | 21 | 29.3 | 71.8 | (44.4-109.7) |
| Female | 7 | 3.0 | 233.0 | (93.4-480.2) | Female | 26 | 22.1 | 117.8 | (76.9-172.6) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | with Standardized incluence | Obs | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------------|-------------|----------|----------------|-----------------------------|-----------|------------|----------|---------------|
| Bladder, Urinary | <u></u> | <u> </u> | <u> </u> | <u>7070 0.</u> | Melanoma of Skin | <u> </u> | =~~ | <u> </u> | <u> </u> |
| Male | 16 | 23.1 | 69.4 | (39.6-112.7) | Male | 23 | 13.4 | 171.2 | (108.5-257.0) |
| Female | 11 | 7.9 | 138.5 | (69.0-247.8) | Female | 18 | 9.7 | 185.1 | (109.6-292.5) |
| Brain and Other Ner | | | | (27.2.2.7) | Multiple Myeloma | | | | |
| Male | 3 | 4.1 | nc | (nc-nc) | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) | Female | 3 | 2.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | , , | Non-Hodgkin Lympho | | | | , , |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 13 | 11.9 | 109.1 | (58.1-186.7) |
| Female | 100 | 76.8 | 130.3 | (106.0-158.4) | Female | 11 | 10.1 | 109.3 | (54.5-195.6) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>nx</u> | | | |
| | | | | | Male | 7 | 8.5 | 82.0 | (32.9-169.0) |
| Female | 1 | 3.0 | nc | (nc-nc) | Female | 7 | 3.7 | 187.6 | (75.1-386.5) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 21 | 33.9 | 62.0 | (38.4-94.8) | | | | | |
| Female | 34 | 30.6 | 111.0 | (76.9-155.2) | Female | 13 | 8.2 | 157.7 | (83.9-269.6) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 5.9 | nc | (nc-nc) | Male | 2 | 6.8 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 11 | 6.7 | 165.1 | (82.3-295.5) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 3 | 1.6 | nc | (nc-nc) | Male | 95 | 87.9 | 108.0 | (87.4-132.1) |
| Female | 1 | 1.0 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 6 | 10.2 | 58.7 | (21.4-127.8) | Male | 2 | 5.6 | nc | (nc-nc) |
| Female | 11 | 5.9 | 185.3 | (92.4-331.5) | Female | 2 | 3.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 3.6 | nc | (nc-nc) | Male | 5 | 2.6 | 195.9 | (63.1-457.2) |
| Female | 0 | 0.9 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 14 | 7.2 | 193.6 | (105.8-324.9) | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 6 | 5.3 | 112.5 | (41.1-244.9) | Female | 5 | 8.0 | 62.7 | (20.2-146.2) |
| Liver and Intrahepat | <u>tic Bile Du</u> | <u>ucts</u> | | | Uteri Corpus and Uter | us, NOS | | | |
| Male | 2 | 4.9 | nc | (nc-nc) | | | | | |
| Female | 2 | 1.6 | nc | (nc-nc) | Female | 20 | 16.5 | 120.9 | (73.8-186.7) |
| Lung and Bronchus | <u>i</u> | | | | All Sites / Types | | | | |
| Male | 20 | 43.3 | 46.2 | (28.2-71.3) | Male | 254 | 303.9 | 83.6 | (73.6-94.5) |
| Female | 20 | 37.4 | 53.5 | (32.7-82.7) | Female | 295 | 264.8 | 111.4 | (99.1-124.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs SIR 95% CI Obs Exp SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 2 Male 0 1.8 (nc-nc) 1.2 (nc-nc) nc Male nc 0 Female 0.6 nc (nc-nc) Female 1 1.0 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma Male 1 0.4 (nc-nc) 0 0.3 (nc-nc) nc Male nc Female 0 0.3 (nc-nc) Female 0 0.2 (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.1 (nc-nc) Male 1 1.1 (nc-nc) nc nc 7 Female 7.3 95.6 (38.3-197.0)Female 0 8.0 (nc-nc) nc Cervix Uteri Oral Cavity and Pharynx 0.9 Male 1 (nc-nc) nc Female 0 0.3 1 0.3 (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 2.9 (nc-nc) 1 nc Female 4 2.3 (nc-nc) **Female** 0 8.0 (nc-nc) nc nc **Esophagus Pancreas** 2 0.5 Male 0 (nc-nc) 0.6 nc Male nc (nc-nc) 0 0 0.5 Female 0.1 nc (nc-nc) Female nc (nc-nc) Hodgkin Lymphoma **Prostate** 9 Male 0 0.2 Male 7.9 114.6 (52.3-217.6)nc (nc-nc) Female 0 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach 0 Male 1 1.0 nc (nc-nc) Male 0.5 (nc-nc) nc Female 1 0.5 (nc-nc) Female 0 0.2 (nc-nc) nc nc Larynx **Testis** 0 0.3 0.3 Male 1 Male (nc-nc) (nc-nc) nc nc 0 0.1 Female (nc-nc) nc **Leukemia Thyroid** 1 0.6 Male 0 0.3 (nc-nc) Male nc (nc-nc) nc Female 0 0.4 nc (nc-nc) Female 0 1.0 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts 0 0.5 Male (nc-nc) nc Female 0 0.1 (nc-nc) Female 0 nc 1.6 nc (nc-nc) Lung and Bronchus All Sites / Types Male 21 79.1 (49.0-121.0)1 3.6 nc (nc-nc) Male 26.5 Female 1 2.9 nc (nc-nc) Female 17 23.0 73.9 (43.0-118.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 0bs Obs SIR 95% CI Ехр SIR 95% CI Exp Bladder, Urinary Melanoma of Skin Male 1 1.0 1 0.6 (nc-nc) nc (nc-nc) Male nc 0 Female 0.3 nc (nc-nc) Female 1 0.5 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 0.2 (nc-nc) 0 0.2 (nc-nc) Male nc Male nc Female 1 0.2 Female 1 0.1 (nc-nc) nc (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 0 Male 0.0 (nc-nc) Male 1 0.5 (nc-nc) nc nc 2 Female 3.8 (nc-nc) Female 0 0.5 (nc-nc) nc nc Oral Cavity and Pharynx Cervix Uteri 0 0.4 Male (nc-nc) nc Female 1 0.2 Female 0 0.2 (nc-nc) (nc-nc) nc nc Colon / Rectum Ovary Male 0 1.5 nc (nc-nc) 2 **Female** 1.3 (nc-nc) **Female** 1 0.4 (nc-nc) nc nc **Esophagus Pancreas** 0 0 0.3 Male 0.3 (nc-nc) Male nc (nc-nc) nc 0 Female 0 0.3 Female 0.1 nc (nc-nc) nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 4 4.0 (nc-nc) nc (nc-nc) nc Female 1 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach 2 Male 0.5 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.3 (nc-nc) Female 0 0.1 (nc-nc) nc nc Larynx Testis 0 0 Male 0.2 Male 0.1 (nc-nc) (nc-nc) nc nc Female 0 0.0 (nc-nc) nc **Leukemia Thyroid** 0 0.3 Male 0 0.2 (nc-nc) Male nc (nc-nc) nc Female 0 0.2 nc (nc-nc) Female 0 0.5 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts 0 Male 0.2 nc (nc-nc) Female 0 0.1 (nc-nc) Female 1 8.0 nc nc (nc-nc) Lung and Bronchus All Sites / Types 3 87.1 (45.0-152.2)Male 1.9 (nc-nc) Male 12 13.8 nc Female 2 1.7 nc (nc-nc) Female 13 12.5 103.6 (55.1-177.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | With Standardized incidence | Obs. | <u>Ехр</u> | <u>SIR</u> | <u>95% CI</u> |
|----------------------------|--------------------|-------------|-------|---------------|-----------------------------|-----------|------------|------------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 13 | 8.1 | 160.9 | (85.6-275.2) | Male | 11 | 4.7 | 233.8 | (116.6-418.4) |
| Female | 4 | 3.4 | nc | (nc-nc) | Female | 4 | 4.1 | nc | (nc-nc) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 1 | 1.5 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 5 | 1.3 | 387.7 | (125.0-904.9) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 6 | 4.2 | 143.3 | (52.3-311.8) |
| Female | 30 | 31.2 | 96.0 | (64.8-137.1) | Female | 1 | 4.3 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 1 | 1.6 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 11.9 | 126.1 | (70.5-208.0) | | | | | |
| Female | 24 | 13.0 | 185.3 | (118.7-275.7) | Female | 2 | 3.4 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 2 | 2.8 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 34 | 30.9 | 110.2 | (76.3-153.9) |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 6 | 3.6 | 166.9 | (61.0-363.4) | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) | Female | 1 | 1.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 4 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 2.6 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) | Female | 4 | 3.3 | nc | (nc-nc) |
| Liver and Intrahepat | <u>tic Bile Du</u> | <u>ıcts</u> | | | Uteri Corpus and Uteri | ıs, NOS | | | |
| Male | 3 | 1.7 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 6 | 6.7 | 90.0 | (32.9-195.9) |
| Lung and Bronchus | <u>i</u> | | | | All Sites / Types | | | | |
| Male | 13 | 15.3 | 85.2 | (45.3-145.7) | Male | 125 | 106.9 | 117.0 | (97.4-139.4) |
| Female | 14 | 15.9 | 88.2 | (48.2-147.9) | Female | 114 | 110.2 | 103.4 | (85.3-124.2) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

| | Ob - | | | • | with Standardized incidence | | | CID | 050/ 01 |
|--------------------|-----------------|------------|-------|-----------------|-----------------------------|------------|------------|-------|---------------|
| DI 11 111 | <u>Obs</u> | <u>Exp</u> | SIR | <u>95% CI</u> | M 1 (C): | <u>Obs</u> | <u>Ехр</u> | SIR | <u>95% CI</u> |
| Bladder, Urinary | 00 | 04.0 | 100.0 | (0, 0, 1, 7, 1) | Melanoma of Skin | 0.0 | 40.0 | 450.7 | (404 4 000 () |
| Male | 39 | 31.9 | 122.2 | (86.9-167.1) | Male | 28 | 18.3 | 152.7 | (101.4-220.6) |
| Female | 9 | 12.8 | 70.4 | (32.1-133.7) | Female | 15 | 15.5 | 96.6 | (54.1-159.4) |
| Brain and Other N | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 7 | 5.6 | 124.0 | (49.7-255.5) | Male | 6 | 4.9 | 121.3 | (44.3-264.0) |
| Female | 8 | 4.9 | 162.6 | (70.0-320.4) | Female | 2 | 3.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 23 | 16.3 | 140.9 | (89.3-211.4) |
| Female | 127 | 118.2 | 107.4 | (89.6-127.8) | Female | 17 | 16.2 | 105.2 | (61.2-168.4) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 11 | 11.5 | 95.3 | (47.5-170.6) |
| Female | 4 | 4.8 | nc | (nc-nc) | Female | 10 | 5.9 | 170.9 | (81.8-314.2) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 59 | 46.6 | 126.6 | (96.4-163.3) | | | | | |
| Female | 55 | 49.0 | 112.1 | (84.5-146.0) | Female | 18 | 12.8 | 140.5 | (83.2-222.1) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 6 | 8.1 | 74.5 | (27.2-162.2) | Male | 17 | 9.3 | 182.1 | (106.0-291.6) |
| Female | 4 | 2.5 | nc | (nc-nc) | Female | 9 | 10.7 | 84.0 | (38.3-159.5) |
| Hodgkin Lymphon | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 3 | 2.3 | nc | (nc-nc) | Male | 131 | 121.2 | 108.1 | (90.4-128.3) |
| Female | 4 | 1.8 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 15 | 14.0 | 107.5 | (60.1-177.3) | Male | 9 | 7.8 | 115.9 | (52.9-220.0) |
| Female | 9 | 9.4 | 96.2 | (43.9-182.6) | Female | 3 | 5.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 5.0 | nc | (nc-nc) | Male | 7 | 3.6 | 196.5 | (78.7-404.8) |
| Female | 1 | 1.4 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | , , | <u>Thyroid</u> | | | | |
| Male | 15 | 10.0 | 150.3 | (84.1-248.0) | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 8 | 8.5 | 93.7 | (40.4-184.7) | Female | 8 | 12.9 | 62.2 | (26.8-122.6) |
| Liver and Intrahep | | | | , | Uteri Corpus and Uteru | | | | , |
| Male | 7 | 6.7 | 104.5 | (41.9-215.3) | | | | | |
| Female | 0 | 2.6 | nc | (nc-nc) | Female | 23 | 25.3 | 91.1 | (57.7-136.6) |
| Lung and Bronchu | | | | () | All Sites / Types | | | | (2111 12010) |
| Male | <u>.s</u> 57 | 60.0 | 95.1 | (72.0-123.2) | Male | 484 | 418.4 | 115.7 | (105.6-126.5) |
| Female | 65 | 59.8 | 108.7 | (83.9-138.5) | Female | 448 | 417.6 | 107.3 | (97.6-117.7) |
| i citiale | 55 | 57.0 | 100.7 | (00.7 100.0) | i citialo | . 10 | 117.0 | 107.0 | (77.0 117.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | min otandaraizaa maraanaa | Obs. | <u>Ехр</u> | SIR | 95% CI |
|------------------------|---------------|-------------|-------|---------------|---------------------------|-----------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 39 | 36.4 | 107.0 | (76.1-146.3) | Male | 10 | 21.4 | 46.7 | (22.3-85.8) |
| Female | 22 | 13.7 | 160.4 | (100.5-242.8) | Female | 21 | 17.1 | 122.8 | (76.0-187.7) |
| Brain and Other No | ervous Sy | <u>stem</u> | | | Multiple Myeloma | | | | |
| Male | 8 | 6.7 | 119.6 | (51.5-235.7) | Male | 9 | 5.7 | 158.6 | (72.4-301.0) |
| Female | 6 | 5.4 | 111.6 | (40.8-243.0) | Female | 6 | 4.2 | 142.2 | (51.9-309.6) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>na</u> | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 17 | 19.0 | 89.2 | (52.0-142.9) |
| Female | 136 | 128.8 | 105.6 | (88.6-124.9) | Female | 16 | 17.6 | 91.0 | (52.0-147.9) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 21 | 13.5 | 155.8 | (96.4-238.1) |
| Female | 7 | 5.3 | 132.2 | (53.0-272.4) | Female | 4 | 6.4 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 72 | 53.6 | 134.4 | (105.1-169.2) | | | | | |
| Female | 49 | 52.6 | 93.1 | (68.8-123.0) | Female | 8 | 14.0 | 56.9 | (24.5-112.2) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 7 | 9.3 | 75.6 | (30.3-155.9) | Male | 12 | 10.7 | 112.0 | (57.8-195.6) |
| Female | 1 | 2.7 | nc | (nc-nc) | Female | 12 | 11.5 | 104.3 | (53.8-182.2) |
| <u>Hodgkin Lymphon</u> | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 3.0 | nc | (nc-nc) | Male | 161 | 137.9 | 116.7 | (99.4-136.2) |
| Female | 3 | 2.3 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 25 | 16.1 | 155.0 | (100.3-228.8) | Male | 13 | 8.9 | 145.4 | (77.4-248.7) |
| Female | 8 | 10.2 | 78.6 | (33.8-154.9) | Female | 10 | 5.6 | 179.3 | (85.8-329.7) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 8 | 5.7 | 139.3 | (60.0-274.5) | Male | 1 | 4.9 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 17 | 11.7 | 145.3 | (84.6-232.7) | Male | 7 | 4.9 | 143.5 | (57.5-295.6) |
| Female | 7 | 9.2 | 76.0 | (30.5-156.7) | Female | 12 | 14.4 | 83.3 | (43.0-145.6) |
| Liver and Intrahep | atic Bile D | <u>ucts</u> | | | Uteri Corpus and Uteri | ıs, NOS | | | |
| Male | 6 | 7.8 | 77.2 | (28.2-168.1) | | | | | |
| Female | 1 | 2.8 | nc | (nc-nc) | Female | 35 | 27.6 | 126.9 | (88.4-176.5) |
| Lung and Bronchu | | | | | All Sites / Types | | | | |
| Male | 72 | 68.2 | 105.6 | (82.6-132.9) | Male | 535 | 482.0 | 111.0 | (101.8-120.8) |
| Female | 53 | 64.9 | 81.7 | (61.2-106.9) | Female | 457 | 453.7 | 100.7 | (91.7-110.4) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

| | Obs | <u>Exp</u> | Served and Ex | 95% CI | with Standardized incluence | Obs | <u>Ехр</u> | SIR | 95% CI |
|--------------------|---------------|------------|---------------|----------------|-----------------------------|-----------|------------|----------|----------------|
| Bladder, Urinary | <u> </u> | <u> </u> | <u> </u> | <u>7070 01</u> | Melanoma of Skin | <u> </u> | <u>LAP</u> | <u> </u> | <u>7070 31</u> |
| Male | 29 | 29.9 | 96.9 | (64.9-139.2) | Male | 16 | 17.2 | 93.1 | (53.2-151.2) |
| Female | 12 | 11.2 | 107.2 | (55.3-187.3) | Female | 20 | 13.8 | 144.8 | (88.4-223.7) |
| Brain and Other N | | | | (33.3.3.7) | Multiple Myeloma | | | | (33.3.3.7) |
| Male | 9 | 5.3 | 169.5 | (77.3-321.8) | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 3 | 4.4 | nc | (nc-nc) | Female | 5 | 3.4 | 146.6 | (47.2-342.1) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 20 | 15.3 | 130.6 | (79.8-201.8) |
| Female | 131 | 104.9 | 124.8 | (104.4-148.2) | Female | 13 | 14.2 | 91.6 | (48.7-156.6) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>nx</u> | | | |
| | | | | | Male | 13 | 10.7 | 121.9 | (64.8-208.5) |
| Female | 2 | 4.3 | nc | (nc-nc) | Female | 4 | 5.2 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 46 | 43.5 | 105.7 | (77.3-140.9) | | | | | |
| Female | 41 | 42.4 | 96.6 | (69.3-131.1) | Female | 12 | 11.3 | 105.8 | (54.6-184.8) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 8 | 7.5 | 106.7 | (45.9-210.2) | Male | 7 | 8.7 | 80.2 | (32.1-165.2) |
| Female | 2 | 2.2 | nc | (nc-nc) | Female | 8 | 9.3 | 85.9 | (37.0-169.3) |
| Hodgkin Lymphon | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 2.2 | nc | (nc-nc) | Male | 140 | 111.8 | 125.2 | (105.3-147.7) |
| Female | 3 | 1.6 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 18 | 13.0 | 138.6 | (82.1-219.1) | Male | 8 | 7.3 | 109.7 | (47.2-216.2) |
| Female | 11 | 8.3 | 132.4 | (66.0-236.9) | Female | 3 | 4.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 8 | 4.6 | 172.7 | (74.4-340.4) | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 7 | 9.4 | 74.5 | (29.8-153.5) | Male | 9 | 3.8 | 235.9 | (107.6-447.8) |
| Female | 9 | 7.5 | 120.5 | (55.0-228.8) | Female | 22 | 11.5 | 190.9 | (119.6-289.0) |
| Liver and Intrahep | | | | | Uteri Corpus and Uteri | us, NOS | | | |
| Male | 7 | 6.2 | 112.8 | (45.2-232.4) | | | | | / |
| Female | 1 | 2.2 | nc | (nc-nc) | Female | 21 | 22.7 | 92.6 | (57.3-141.6) |
| Lung and Bronchu | | | | | All Sites / Types | | | | |
| Male | 49 | 56.0 | 87.5 | (64.7-115.7) | Male | 440 | 390.1 | 112.8 | (102.5-123.8) |
| Female | 62 | 53.3 | 116.2 | (89.1-149.0) | Female | 414 | 368.6 | 112.3 | (101.7-123.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр SIR 95% CI Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin 5.7 6 105.3 (38.5-229.2)6 3.5 171.9 (62.8-374.1)Male Male 5 Female 2.0 251.1 (80.9-585.9)Female 1 2.7 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 (nc-nc) 2 0.9 Male 1.1 nc Male nc (nc-nc) Female 3 8.0 (nc-nc) Female 1 0.6 nc (nc-nc) nc Non-Hodgkin Lymphoma **Breast** Male 0 0.2 (nc-nc) Male 1 3.1 (nc-nc) nc nc 2 Female 18 20.9 86.0 (51.0-136.0)Female 2.6 (nc-nc) nc Cervix Uteri Oral Cavity and Pharynx 2.3 Male 1 (nc-nc) nc 1 0.9 0 1.0 Female (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 6 8.6 70.0 (25.6-152.4)5 Female 7.6 65.8 (21.2-153.6)**Female** 1 2.2 (nc-nc) nc **Esophagus Pancreas** 0 1 1.5 (nc-nc) 1.7 Male nc Male nc (nc-nc) 0 Female 1 0.4 nc (nc-nc) Female 1.7 nc (nc-nc) **Prostate** Hodgkin Lymphoma Male 0 0.4 Male 16 22.8 70.3 (40.2-114.2)nc (nc-nc) Female 0 (nc-nc) 0.3 nc Kidney and Renal Pelvis Stomach Male 2 2.7 nc (nc-nc) Male 1 1.4 (nc-nc) nc Female 0 1.6 (nc-nc) Female 0 8.0 (nc-nc) nc nc Larynx **Testis** 2 0.7 1 1.0 Male Male (nc-nc) (nc-nc) nc nc 0 Female 0.2 (nc-nc) nc **Leukemia Thyroid** 4 1.9 Male 8.0 Male nc (nc-nc) 1 nc (nc-nc) Female 1 1.3 nc (nc-nc) Female 3 2.4 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 1.3 (nc-nc) nc Female 0 0.4 Female 4 4.5 nc (nc-nc) nc (nc-nc) Lung and Bronchus All Sites / Types

• Obs = observed case count; Exp = expected case count;

10.8

9.7

7

7

Male

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(25.9-133.5)

(29.0-149.0)

• Shading indicates the statistical significance of the SIR at 95% level of probability;

64.8

72.3

• nc = The SIR and 95% CI were not calculated when Obs < 5;

77.9

70.1

61

60

Male

Female

78.3

85.6

(59.9-100.6)

(65.3-110.2)

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр 95% CI Ехр SIR 95% CI SIR Obs Bladder, Urinary Melanoma of Skin 39 33.6 116.2 (82.6-158.8) Male 16.6 247.3 (177.4 - 335.4)Male 41 Female 17 11.7 145.7 (84.8-233.3)Female 18 12.1 149.1 (88.3-235.6) **Brain and Other Nervous System** Multiple Myeloma 2 4.7 (nc-nc) 2 4.9 (nc-nc) Male nc Male nc 4 3.8 (nc-nc) Female 3 3.6 Female nc nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 1 0.9 (nc-nc) Male 14 15.2 92.0 (50.3-154.4)nc Female 101 97.2 103.9 (84.6-126.2) Female 14.2 77.3 (38.5-138.3)11 Oral Cavity and Pharynx Cervix Uteri 10.0 140.4 Male 14 (76.7-235.7)5 3.5 8 5.0 (68.9 - 315.2)Female 144.9 (46.7-338.2)Female 160.0 Colon / Rectum Ovary Male 53 46.8 113.2 (84.8-148.0) Female 41 43.7 93.8 (67.3-127.3)Female 15 10.7 139.7 (78.1-230.4)**Esophagus Pancreas** 7 7 7.9 89.0 9.5 (35.7-183.4)73.8 (29.6-152.0)Male Male 2 2.3 Female 8 9.7 82.3 Female nc (nc-nc) (35.4-162.1)Hodgkin Lymphoma **Prostate** Male 2 1.6 Male 168 118.0 142.3 (121.6-165.6) nc (nc-nc) Female 0 1.2 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 15 12.8 117.2 (65.5-193.3)Male 1 8.0 nc (nc-nc) Female 7 8.3 84.8 (34.0-174.7)Female 2 (nc-nc) 4.6 nc Larynx **Testis** 125.7 2 6 4.8 (45.9-273.7) Male 2.0 Male (nc-nc) nc 0 Female 1.3 (nc-nc) nc **Leukemia Thyroid** 12 9.4 127.2 3.0 Male (65.7-222.3)Male 4 nc (nc-nc) Female 10 7.1 140.4 (67.2-258.3) Female 8 8.7 91.5 (39.4-180.3)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS

• Obs = observed case count; Exp = expected case count;

6.1

2.3

61.7

55.7

9

0

42

62

Male

Male

Female

Female

Lung and Bronchus

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(67.5-280.6)

(49.1-92.1)

(85.4-142.8)

(nc-nc)

Shading indicates the statistical significance of the SIR at 95% level of probability;

147.8

nc

68.1

111.4

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

Male

Female

All Sites / Types

25

481

376

21.4

407.5

357.2

116.6

118.0

105.3

(75.4-172.2)

(107.7-129.1)

(94.9-116.5)

Dighton

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | , with Standardized incluence K | Obs | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|-------------|-------|--------------|---------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 5 | 6.9 | 72.6 | (23.4-169.4) | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 4 | 2.5 | nc | (nc-nc) | Female | 3 | 3.5 | nc | (nc-nc) |
| Brain and Other Ner | vous Sys | | | , , | Multiple Myeloma | | | | , |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 3 | 1.1 | nc | (nc-nc) | Female | 1 | 8.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 9 | 3.8 | 239.5 | (109.3-454.7) |
| Female | 26 | 25.6 | 101.5 | (66.3-148.7) | Female | 5 | 3.3 | 151.1 | (48.7-352.6) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | Female | 1 | 1.2 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 14 | 10.3 | 135.4 | (74.0-227.2) | | | | | |
| Female | 9 | 9.6 | 93.4 | (42.6-177.3) | Female | 1 | 2.7 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 3 | 1.8 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | Female | 1 | 2.1 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 2 | 0.6 | nc | (nc-nc) | Male | 22 | 27.2 | 81.0 | (50.7-122.6) |
| Female | 1 | 0.4 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 7 | 3.2 | 216.7 | (86.8-446.6) | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) | Female | 3 | 1.0 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 3 | 1.1 | nc | (nc-nc) | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 2.3 | nc | (nc-nc) | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 4 | 1.8 | nc | (nc-nc) | Female | 3 | 3.1 | nc | (nc-nc) |
| Liver and Intrahepat | ic Bile Du | | | | Uteri Corpus and Uterus, | <u>NOS</u> | | | |
| Male | 0 | 1.6 | nc | (nc-nc) | | | | | |
| Female | 2 | 0.5 | nc | (nc-nc) | Female | 3 | 5.5 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 9 | 13.1 | 68.9 | (31.5-130.9) | Male | 91 | 94.1 | 96.7 | (77.9-118.7) |
| Female | 17 | 12.0 | 141.2 | (82.2-226.0) | Female | 101 | 87.4 | 115.5 | (94.1-140.4) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр SIR 95% CI Obs Ехр SIR 95% CI Bladder, Urinary Melanoma of Skin 5 Male 6 5.3 113.7 (41.5-247.5)3.9 129.5 (41.7-302.2)Male 2 Female 1 1.9 nc (nc-nc) Female 3.3 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 3 1.4 (nc-nc) 1 0.9 Male nc Male nc (nc-nc) Female 1 1.0 (nc-nc) Female 0 0.6 nc (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 5 Male 1 0.2 (nc-nc) Male 3.3 151.1 (48.7 - 352.5)nc 25 Female 22.2 112.5 (72.8-166.0)Female 1 2.7 (nc-nc) nc Cervix Uteri Oral Cavity and Pharynx 3 2.4 Male (nc-nc) nc 0 1.2 1 1.0 Female (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 7 8.3 84.6 (33.9-174.4)7 Female 7.3 95.4 (38.2-196.5)**Female** 1 2.3 (nc-nc) nc **Esophagus Pancreas** 2 0 1.5 (nc-nc) 1.6 Male nc Male nc (nc-nc) 2 2 Female 0.4 nc (nc-nc) Female 1.5 nc (nc-nc) **Prostate** Hodgkin Lymphoma Male 0 0.7 Male 15 20.9 71.7 (40.1-118.2)nc (nc-nc) Female 0 0.5 (nc-nc) nc Kidney and Renal Pelvis Stomach 2 Male 1 2.8 nc (nc-nc) Male 1.4 (nc-nc) nc Female 2 1.6 (nc-nc) Female 0 8.0 (nc-nc) nc nc Larynx **Testis** 0.9 1 1 1.3 Male (nc-nc) Male (nc-nc) nc nc 0 Female 0.2 (nc-nc) nc **Leukemia Thyroid** 1 2.0 Male 0 1.1 Male nc (nc-nc) (nc-nc) nc Female 3 1.5 nc (nc-nc) Female 2 3.4 nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 1.3 (nc-nc) nc Female 0 0.4 Female 4 4.5 nc (nc-nc) nc (nc-nc) Lung and Bronchus All Sites / Types 7 10.0 70.1 (65.4-108.1) Male (28.1-144.5)Male 65 76.6 84.8

• Obs = observed case count; Exp = expected case count;

9.0

Female

10

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(53.1-203.9)

Shading indicates the statistical significance of the SIR at 95% level of probability;

110.9

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

67

72.9

91.9

(71.2-116.7)

Dover

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | , with Standardized includince it | <u>Obs</u> | <u>Ехр</u> | SIR | <u>95% CI</u> |
|----------------------|--------------|-------------|-------|--------------|-----------------------------------|------------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 1 | 6.2 | nc | (nc-nc) | Male | 9 | 3.9 | 232.5 | (106.1-441.3) |
| Female | 2 | 1.9 | nc | (nc-nc) | Female | 6 | 2.9 | 209.5 | (76.5-456.0) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 3 | 0.9 | nc | (nc-nc) | Female | 2 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 24 | 22.2 | 107.9 | (69.1-160.6) | Female | 2 | 2.5 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 9.4 | 74.3 | (29.8-153.1) | | | | | |
| Female | 7 | 6.9 | 100.7 | (40.4-207.5) | Female | 4 | 2.3 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 1.7 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 1 | 1.5 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>l</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 41 | 25.8 | 158.9 | (114.0-215.6) |
| Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 2 | 3.0 | nc | (nc-nc) | Male | 4 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) | Female | 4 | 2.7 | nc | (nc-nc) |
| Liver and Intrahepat | tic Bile Du | <u>icts</u> | | | Uteri Corpus and Uterus, | NOS | | | |
| Male | 0 | 1.5 | nc | (nc-nc) | | | | | |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 5 | 4.9 | 102.7 | (33.1-239.6) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 8 | 12.0 | 66.6 | (28.7-131.3) | Male | 87 | 86.6 | 100.5 | (80.5-123.9) |
| Female | 6 | 9.5 | 63.0 | (23.0-137.2) | Female | 75 | 70.8 | 105.9 | (83.3-132.8) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

| | <u>Obs</u> | Exp | Serveu and Ex | 95% CI | with Standardized incluence | Obs | <u>Exp</u> | SIR | 95% CI |
|------------------------|---------------|-------------|---------------|------------------|-----------------------------|------------|------------|-------------|---|
| Bladder, Urinary | 003 | LAP | <u> 3111</u> | <u>73 / 6 CI</u> | Melanoma of Skin | <u>OD3</u> | <u>LVh</u> | <u>3110</u> | <u>73 /0 CI</u> |
| Male | 39 | 26.9 | 145.1 | (103.2-198.4) | Male | 11 | 17.2 | 64.0 | (31.9-114.5) |
| Female | 12 | 10.1 | 118.7 | (61.3-207.4) | Female | 16 | 14.7 | 109.0 | (62.2-177.0) |
| Brain and Other No | | | 110.7 | (01.3 207.4) | Multiple Myeloma | 10 | 14.7 | 107.0 | (02.2 177.0) |
| Male | 8 | 5.7 | 139.8 | (60.2-275.4) | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 2 | 4.6 | nc | (nc-nc) | Female | 3 | 3.1 | nc | (nc-nc) |
| <u>Breast</u> | 2 | 1.0 | 110 | (ne ne) | Non-Hodgkin Lymphor | | 0.1 | 110 | (He He) |
| <u>a. a.a.</u> Male | 0 | 0.8 | nc | (nc-nc) | Male | 12 | 15.0 | 79.8 | (41.2-139.5) |
| Female | 116 | 106.2 | 109.2 | (90.3-131.0) | Female | 23 | 13.4 | 171.2 | (108.5-257.0) |
| Cervix Uteri | | | | (1010 1011) | Oral Cavity and Pharyr | | | | (************************************** |
| | | | | | Male | 13 | 10.9 | 119.4 | (63.5-204.1) |
| Female | 3 | 4.9 | nc | (nc-nc) | Female | 9 | 5.1 | 178.1 | (81.3-338.1) |
| Colon / Rectum | | | | , , | <u>Ovary</u> | | | | , |
| Male | 44 | 40.5 | 108.6 | (78.9-145.7) | | | | | |
| Female | 46 | 37.7 | 122.0 | (89.3-162.7) | Female | 12 | 11.3 | 106.4 | (54.9-185.9) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 7 | 7.1 | 97.9 | (39.2-201.7) | Male | 10 | 8.0 | 124.3 | (59.5-228.6) |
| Female | 5 | 2.0 | 253.2 | (81.6-590.9) | Female | 8 | 8.3 | 96.6 | (41.6-190.4) |
| Hodgkin Lymphon | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 2.6 | nc | (nc-nc) | Male | 114 | 107.9 | 105.7 | (87.2-127.0) |
| Female | 1 | 2.0 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 15 | 13.0 | 115.5 | (64.6-190.6) | Male | 5 | 6.6 | 75.3 | (24.3-175.7) |
| Female | 11 | 8.0 | 136.8 | (68.2-244.8) | Female | 4 | 3.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 7 | 4.5 | 156.2 | (62.6-321.9) | Male | 8 | 4.6 | 172.8 | (74.4-340.5) |
| Female | 3 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 8 | 9.2 | 86.7 | (37.3-170.9) | Male | 6 | 4.3 | 138.7 | (50.6-301.9) |
| Female | 7 | 7.2 | 97.5 | (39.1-200.9) | Female | 18 | 13.6 | 132.4 | (78.4-209.3) |
| Liver and Intrahep | atic Bile D | <u>ucts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 7 | 6.2 | 112.4 | (45.0-231.7) | | | | | |
| Female | 2 | 2.0 | nc | (nc-nc) | Female | 30 | 22.6 | 132.9 | (89.6-189.7) |
| Lung and Bronchu | <u>IS</u> | | | | All Sites / Types | | | | |
| Male | 60 | 52.0 | 115.5 | (88.1-148.7) | Male | 393 | 374.1 | 105.0 | (94.9-116.0) |
| Female | 59 | 50.0 | 118.0 | (89.8-152.2) | Female | 424 | 358.4 | 118.3 | (107.3-130.1) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр SIR 95% CI Obs Ехр SIR 95% CI Bladder, Urinary Melanoma of Skin Male 4 10.9 (nc-nc) 4 6.6 nc Male nc (nc-nc) 8 Female 4 3.8 nc (nc-nc) Female 5.3 149.7 (64.4-294.9)**Brain and Other Nervous System** Multiple Myeloma 1 2.2 (nc-nc) 1 1.7 (nc-nc) Male nc Male nc Female 0 1.7 (nc-nc) Female 0 1.2 nc (nc-nc) nc Non-Hodgkin Lymphoma **Breast** Male 0 0.3 (nc-nc) Male 3 5.9 (nc-nc) nc nc 34 Female 38.7 87.8 (60.8-122.6)Female 4 5.1 (nc-nc) nc Oral Cavity and Pharynx Cervix Uteri Male 6 4.2 143.3 (52.3-311.9)0 1.8 2 1.9 Female (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 16 99.2 (56.6-161.0)16.1 Female 143.7 Female 14 14.7 95.2 (52.0-159.7)6 4.2 (52.5-312.8)**Esophagus Pancreas** 2 3.2 1 2.8 (nc-nc) Male nc Male nc (nc-nc) 0 Female 3 3.2 Female 8.0 nc (nc-nc) nc (nc-nc) Hodgkin Lymphoma **Prostate** 3 Male 1.0 41 41.9 98.0 (70.3-132.9)nc (nc-nc) Male Female 1 0.7 (nc-nc) nc Kidney and Renal Pelvis Stomach 5 (32.4-234.7)Male 5.0 100.6 Male 1 2.7 (nc-nc) nc Female 2 3.0 (nc-nc) Female 0 1.5 (nc-nc) nc nc Larynx **Testis** 1 1 1.7 1.7 Male (nc-nc) Male (nc-nc) nc nc 0 Female 0.5 (nc-nc) nc **Leukemia Thyroid** 1.6 3 Male 3.6 nc (nc-nc) Male 1 nc (nc-nc) Female 2 2.7 nc (nc-nc) Female 6 4.8 123.9 (45.3-269.7)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS 2 Male 2.4 (nc-nc) nc 7 Female 0 8.0 Female 8.2 85.3 (34.2-175.8)nc (nc-nc) Lung and Bronchus All Sites / Types

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

20.5

18.5

17

12

Male

Female

• 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(48.3-133.0)

(33.5-113.3)

Shading indicates the statistical significance of the SIR at 95% level of probability;

83.0

64.9

• nc = The SIR and 95% CI were not calculated when Obs < 5;

125

114

Male

Female

85.2

85.4

146.7

133.4

(70.9-101.5)

(70.5-102.6)

Dunstable

| | <u>Obs</u> | <u>Exp</u> | erved and Exp SIR | 95% CI | with Standardized incluence Ka | Obs | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|------------|----------------------|----------------|--------------------------------|------------|------------|------------|---|
| Bladder, Urinary | <u> </u> | <u>LXÞ</u> | <u>ont</u> | <u>7570 01</u> | Melanoma of Skin | <u> </u> | <u>LXP</u> | <u>ont</u> | <u>7070 GI</u> |
| Male | 2 | 2.3 | nc | (nc-nc) | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) | Female | 1 | 1.4 | nc | (nc-nc) |
| Brain and Other Ner | | | | (, | Multiple Myeloma | • | | | (************************************** |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 3 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | , | Non-Hodgkin Lymphoma | | | | , , |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 17 | 10.1 | 168.7 | (98.2-270.0) | Female | 1 | 1.1 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 2 | 0.4 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 1 | 3.7 | nc | (nc-nc) | | | | | |
| Female | 4 | 2.8 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 9 | 10.5 | 85.9 | (39.2-163.0) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 2 | 1.4 | nc | (nc-nc) |
| Liver and Intrahepat | tic Bile Du | | | | Uteri Corpus and Uterus, | <u>NOS</u> | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 4 | 2.1 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 3 | 4.6 | nc | (nc-nc) | Male | 29 | 35.3 | 82.1 | (55.0-117.9) |
| Female | 4 | 3.8 | nc | (nc-nc) | Female | 41 | 30.8 | 133.0 | (95.4-180.4) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

| | <u>Obs</u> | <u>Exp</u> | Served and Ex | 95% CI | , Willi Standardized incluence | Obs | -2003 <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|-------------|---------------|----------------|--------------------------------|---------|---------------------|------------|----------------|
| Bladder, Urinary | <u> </u> | LAP | <u>one</u> | <u>7576 01</u> | Melanoma of Skin | 003 | <u>LXP</u> | <u>ont</u> | <u>7570 01</u> |
| Male | 11 | 15.5 | 71.2 | (35.5-127.3) | Male | 23 | 9.7 | 236.5 | (149.9-354.9) |
| Female | 5 | 5.8 | 85.8 | (27.6-200.1) | Female | 24 | 8.0 | 298.2 | (191.0-443.7) |
| Brain and Other Ner | | | | (=:::==:::) | Multiple Myeloma | | | | (, |
| Male | 2 | 3.2 | nc | (nc-nc) | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 5 | 2.6 | 195.5 | (63.0-456.2) | Female | 2 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | , | Non-Hodgkin Lymphor | | | | , |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 11 | 8.5 | 129.1 | (64.4-231.0) |
| Female | 69 | 61.8 | 111.6 | (86.8-141.2) | Female | 12 | 7.7 | 156.5 | (80.8-273.3) |
| Cervix Uteri | | | | , | Oral Cavity and Pharyr | | | | , , |
| | | | | | Male | | 6.7 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) | Female | 6 | 2.9 | 205.8 | (75.2-448.0) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 27 | 23.5 | 114.9 | (75.7-167.2) | | | | | |
| Female | 21 | 22.8 | 92.0 | (56.9-140.6) | Female | 3 | 6.6 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 6 | 4.2 | 141.9 | (51.8-308.9) | Male | 5 | 4.7 | 106.1 | (34.2-247.5) |
| Female | 0 | 1.1 | nc | (nc-nc) | Female | 4 | 4.9 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 100 | 63.8 | 156.8 | (127.6-190.7) |
| Female | 2 | 0.9 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 5 | 7.5 | 66.4 | (21.4-155.1) | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 3 | 4.6 | nc | (nc-nc) | Female | 2 | 2.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 2.7 | nc | (nc-nc) | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 5.2 | 193.0 | (92.4-354.9) | Male | 6 | 2.3 | 261.0 | (95.3-568.2) |
| Female | 2 | 4.2 | nc | (nc-nc) | Female | 10 | 7.1 | 140.8 | (67.4-258.9) |
| Liver and Intrahepat | tic Bile Du | <u>ıcts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 1 | 3.7 | nc | (nc-nc) | | | | | |
| Female | 3 | 1.2 | nc | (nc-nc) | Female | 14 | 13.2 | 106.0 | (57.9-177.8) |
| Lung and Bronchus | <u>i</u> | | | | All Sites / Types | | | | |
| Male | 20 | 29.6 | 67.6 | (41.3-104.4) | Male | 254 | 215.7 | 117.7 | (103.7-133.1) |
| Female | 30 | 27.5 | 109.0 | (73.5-155.6) | Female | 241 | 206.4 | 116.8 | (102.5-132.5) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | With Standardized incidence | Obs. | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------------|-------------|-------|---------------|-----------------------------|-----------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 12 | 11.9 | 100.6 | (51.9-175.8) | Male | 10 | 7.9 | 127.2 | (60.9-233.9) |
| Female | 1 | 4.4 | nc | (nc-nc) | Female | 15 | 6.7 | 223.7 | (125.1-369.0) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 1 | 2.6 | nc | (nc-nc) | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 8 | 6.9 | 116.7 | (50.2-229.9) |
| Female | 52 | 48.3 | 107.6 | (80.4-141.1) | Female | 10 | 6.0 | 168.1 | (80.5-309.1) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 8 | 5.1 | 156.5 | (67.4-308.4) |
| Female | 1 | 2.3 | nc | (nc-nc) | Female | 4 | 2.3 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 18.2 | 82.3 | (46.0-135.7) | | | | | |
| Female | 27 | 16.9 | 160.0 | (105.4-232.9) | Female | 6 | 5.1 | 117.2 | (42.8-255.1) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 3.2 | nc | (nc-nc) | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 5 | 3.7 | 136.8 | (44.1-319.3) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Male | 45 | 49.1 | 91.6 | (66.8-122.6) |
| Female | 2 | 0.9 | nc | (nc-nc) | | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 4 | 5.9 | nc | (nc-nc) | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.6 | 168.6 | (61.6-367.0) | Female | 2 | 1.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 4.2 | nc | (nc-nc) | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) | Female | 6 | 6.3 | 94.6 | (34.6-206.0) |
| Liver and Intrahepat | <u>tic Bile Du</u> | <u>ıcts</u> | | | Uteri Corpus and Uteri | us, NOS | | | |
| Male | 1 | 2.9 | nc | (nc-nc) | | | | | |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 9 | 10.3 | 87.2 | (39.8-165.5) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 28 | 23.1 | 121.1 | (80.5-175.0) | Male | 157 | 169.5 | 92.6 | (78.7-108.3) |
| Female | 17 | 21.5 | 79.2 | (46.1-126.9) | Female | 181 | 161.0 | 112.4 | (96.6-130.0) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

| | Ol | | - | | with Standardized incluence Ra | | | CID | 050/ 01 |
|-----------------------|------------|------------|-------|---------------|--------------------------------|------------|------------|-------|---------------|
| | <u>Obs</u> | <u>Exp</u> | SIR | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | SIR | <u>95% CI</u> |
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 4 | 2.4 | nc | (nc-nc) | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| Brain and Other Nerv | • | | | | Multiple Myeloma | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 8 | 8.2 | 97.6 | (42.0-192.4) | Female | 2 | 1.0 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 3.6 | nc | (nc-nc) | | | | | |
| Female | 3 | 3.0 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 4 | 9.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | , , |
| Kidney and Renal Pe | elvis | | | | <u>Stomach</u> | | | | |
| Male | 2 | 1.1 | nc | (nc-nc) | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | , | <u>Testis</u> | | | | , , |
| Male | 0 | 0.4 | nc | (nc-nc) | | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | (|
| <u>Leukemia</u> | | | | (/ | <u>Thyroid</u> | | | | |
| Male | 3 | 0.8 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| Liver and Intrahepati | | | | (1.0.1.0) | Uteri Corpus and Uterus, | | | | (1.0 1.0) |
| Male | 0 | 0.5 | nc | (nc-nc) | oten corpus una oteras, | 1100 | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 1.7 | nc | (nc-nc) |
| Lung and Bronchus | J | ٧.٤ | 110 | (no no) | All Sites / Types | • | 1.7 | 110 | (110 110) |
| Male | 7 | 4.6 | 152.5 | (61.1-314.2) | Male | 34 | 32.8 | 103.6 | (71.7-144.8) |
| Female | 5 | 3.8 | 130.3 | (42.0-304.0) | Female | 25 | 27.8 | 90.0 | (58.2-132.8) |
| гентаве | ິນ | ა.0 | 130.3 | (42.0-304.0) | remale | 20 | 21.0 | 90.0 | (30.2-132.8) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

| | <u>Obs</u> | <u>Exp</u> | SELVED AND EX | 95% CI | , With Standardized incluence | Obs | -2003 <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|-------------|---------------|----------------|-------------------------------|-----------|---------------------|--------------|----------------|
| Bladder, Urinary | <u> </u> | <u>=F</u> | <u>v</u> | <u>7070 01</u> | Melanoma of Skin | <u> </u> | <u> </u> | <u>5.1.1</u> | <u>7070 01</u> |
| Male | 21 | 19.7 | 106.4 | (65.9-162.7) | Male | 14 | 11.1 | 126.5 | (69.1-212.2) |
| Female | 8 | 7.9 | 101.5 | (43.7-200.0) | Female | 8 | 9.1 | 88.3 | (38.0-173.9) |
| Brain and Other Ner | | | | (11 | Multiple Myeloma | | | | (3.3.3.3.7) |
| Male | 6 | 3.4 | 176.4 | (64.4-383.9) | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) | Female | 1 | 2.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | na | | | |
| Male | 2 | 0.6 | nc | (nc-nc) | Male | 12 | 9.9 | 120.8 | (62.4-211.0) |
| Female | 80 | 69.8 | 114.7 | (90.9-142.7) | Female | 13 | 9.8 | 132.0 | (70.2-225.7) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 5 | 2.8 | 181.7 | (58.6-424.0) | Female | 2 | 3.5 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 21 | 28.6 | 73.3 | (45.4-112.1) | | | | | |
| Female | 22 | 30.6 | 71.9 | (45.1-108.9) | Female | 14 | 7.6 | 184.0 | (100.5-308.7) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 3 | 4.9 | nc | (nc-nc) | Male | 2 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) | Female | 8 | 6.7 | 119.7 | (51.6-235.9) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 3 | 1.3 | nc | (nc-nc) | Male | 78 | 73.3 | 106.4 | (84.1-132.8) |
| Female | 1 | 1.0 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 8 | 8.5 | 94.5 | (40.7-186.3) | Male | 5 | 4.8 | 104.1 | (33.6-243.0) |
| Female | 3 | 5.6 | nc | (nc-nc) | Female | 0 | 3.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 4 | 3.0 | nc | (nc-nc) | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 0.9 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 6.1 | nc | (nc-nc) | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 4 | 5.2 | nc | (nc-nc) | Female | 2 | 7.2 | nc | (nc-nc) |
| Liver and Intrahepat | tic Bile Du | <u>icts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 1 | 4.1 | nc | (nc-nc) | | | | | |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 17 | 14.7 | 115.6 | (67.3-185.1) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 25 | 36.9 | 67.8 | (43.9-100.1) | Male | 233 | 255.0 | 91.4 | (80.0-103.9) |
| Female | 21 | 36.3 | 57.9 | (35.8-88.5) | Female | 242 | 250.9 | 96.4 | (84.7-109.4) |

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

| | <u>Obs</u> | <u>Exp</u> | SIR | 95% CI | , with Standardized incidence | Obs | <u>Ехр</u> | <u>SIR</u> | <u>95% CI</u> |
|----------------------------|--------------|-------------|-------|--------------|-------------------------------|-----------|------------|------------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 18 | 11.4 | 157.9 | (93.5-249.6) | Male | 12 | 5.7 | 210.1 | (108.4-367.0) |
| Female | 6 | 3.5 | 170.7 | (62.3-371.5) | Female | 4 | 3.9 | nc | (nc-nc) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 3 | 1.6 | nc | (nc-nc) | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 1 | 1.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | <u>na</u> | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 38 | 30.8 | 123.4 | (87.3-169.4) | Female | 3 | 4.3 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 19 | 16.0 | 118.7 | (71.4-185.4) | | | | | |
| Female | 14 | 12.8 | 109.0 | (59.6-183.0) | Female | 3 | 3.4 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 2.7 | nc | (nc-nc) | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 3 | 2.9 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>l</u> | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 59 | 40.6 | 145.3 | (110.6-187.5) |
| Female | 0 | 0.4 | nc | (nc-nc) | | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 2 | 4.4 | nc | (nc-nc) | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.6 | nc | (nc-nc) | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 3.2 | 154.4 | (49.7-360.3) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) | Female | 1 | 3.0 | nc | (nc-nc) |
| Liver and Intrahepat | ic Bile Du | <u>icts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 0 | 2.1 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 9 | 6.8 | 132.2 | (60.3-251.0) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 13 | 21.2 | 61.4 | (32.7-105.0) | Male | 161 | 139.9 | 115.0 | (98.0-134.2) |
| Female | 10 | 17.2 | 58.2 | (27.9-107.0) | Female | 112 | 110.3 | 101.5 | (83.6-122.1) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр SIR 95% CI Obs SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 9 11 17.8 61.8 (30.8-110.6)10.8 83.6 (38.2-158.8)Male Male 7.0 8 Female 4 nc (nc-nc) Female 9.2 86.7 (37.3-170.9)**Brain and Other Nervous System** Multiple Myeloma 5 3.4 147.9 2 2.8 (nc-nc) Male (47.7 - 345.3)Male nc 5 2.8 176.3 (56.8-411.4) Female 4 2.1 Female nc (nc-nc) Non-Hodgkin Lymphoma **Breast** 7 Male 0 0.5 (nc-nc) Male 9.5 73.6 (29.5-151.6)nc Female 68 67.4 100.8 (78.3-127.8)Female 8 9.1 88.2 (38.0-173.7)Cervix Uteri Oral Cavity and Pharynx 11 6.7 163.3 (81.4-292.1)Male 2 3.0 3 3.3 Female (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 38 26.4 144.0 (101.9-197.7)8 109.7 Female 27 26.9 100.3 (66.1-145.9)**Female** 7.3 (47.2-216.1) **Esophagus Pancreas** 4 5.2 4.5 132.2 (48.3-287.7)Male 6 Male nc (nc-nc) Female 5.9 Female 1 1.4 nc (nc-nc) 6 102.5 (37.4-223.1)Hodgkin Lymphoma **Prostate** 2 1.5 Male 56 66.0 84.8 Male nc (nc-nc) (64.0-110.1)Female 1 1.2 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 8 8.0 100.3 (43.2-197.7)Male 5 4.4 113.7 (36.6-265.4)Female 3 5.3 (nc-nc) Female 0 2.9 nc nc (nc-nc) Larynx **Testis** 0 4 2.8 2.6 Male (nc-nc) Male (nc-nc) nc nc 2 Female 8.0 (nc-nc) nc **Leukemia Thyroid** 0 2.5 Male 4 5.8 nc (nc-nc) Male (nc-nc) nc Female 5 4.8 104.8 (33.8-244.5)Female 7 8.0 87.1 (34.9-179.4)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 3.9 4 nc (nc-nc)

• Obs = observed case count; Exp = expected case count;

1.4

33.1

32.9

Female

Male

Female

Lung and Bronchus

2

41

23

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

(89.0-168.2)

(44.3-104.9)

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

124.0

69.9

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

Male

Female

All Sites / Types

8

232

215

56.2

98.4

91.3

14.2

235.7

235.4

(24.2-110.7)

(86.2-111.9)

(79.5-104.4)

Easton

| | Obs | <u>Exp</u> | SIR | 95% CI | , With Standardized incluence | Obs | <u>Ехр</u> | SIR | <u>95% CI</u> |
|----------------------|--------------|-------------|----------|-----------------|-------------------------------|-----------|------------|----------|-----------------|
| Bladder, Urinary | <u> </u> | =~F | <u>v</u> | <u> 7070 01</u> | Melanoma of Skin | <u> </u> | <u> </u> | <u> </u> | <u> 7070 U.</u> |
| Male | 21 | 18.8 | 111.6 | (69.0-170.6) | Male | 26 | 12.8 | 203.3 | (132.7-297.8) |
| Female | 2 | 6.7 | nc | (nc-nc) | Female | 12 | 10.9 | 110.1 | (56.8-192.3) |
| Brain and Other Ner | | | | (/ | Multiple Myeloma | | | | (3333) |
| Male | 1 | 4.3 | nc | (nc-nc) | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) | Female | 0 | 2.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | , , | Non-Hodgkin Lymphor | | | | , , |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 18 | 11.1 | 162.9 | (96.5-257.4) |
| Female | 89 | 77.7 | 114.5 | (91.9-140.9) | Female | 3 | 9.2 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 5 | 8.5 | 59.1 | (19.1-138.0) |
| Female | 6 | 3.7 | 160.5 | (58.6-349.4) | Female | 3 | 3.6 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 30 | 29.1 | 103.1 | (69.6-147.3) | | | | | |
| Female | 19 | 25.5 | 74.6 | (44.9-116.4) | Female | 5 | 8.2 | 60.9 | (19.6-142.0) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 5 | 5.2 | 95.5 | (30.8-222.9) | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) | Female | 6 | 5.5 | 109.5 | (40.0-238.4) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 4 | 2.0 | nc | (nc-nc) | Male | 88 | 79.6 | 110.6 | (88.7-136.2) |
| Female | 3 | 1.6 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 12 | 9.6 | 125.1 | (64.6-218.5) | Male | 5 | 4.7 | 106.7 | (34.4-249.1) |
| Female | 4 | 5.6 | nc | (nc-nc) | Female | 1 | 2.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 3.4 | nc | (nc-nc) | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 6.7 | nc | (nc-nc) | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 6 | 5.0 | 119.5 | (43.6-260.0) | Female | 8 | 10.7 | 74.9 | (32.3-147.7) |
| Liver and Intrahepat | tic Bile Du | <u>icts</u> | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 3 | 4.7 | nc | (nc-nc) | | | | | |
| Female | 2 | 1.4 | nc | (nc-nc) | Female | 18 | 16.5 | 108.8 | (64.5-172.0) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 32 | 36.5 | 87.6 | (59.9-123.6) | Male | 283 | 272.4 | 103.9 | (92.1-116.7) |
| Female | 36 | 32.9 | 109.6 | (76.7-151.7) | Female | 251 | 253.4 | 99.0 | (87.2-112.1) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

| Male | | Obs | | erved and Exp SIR | 95% CI | with Standardized incluence Ka | Obs | | SIR | <u>95% CI</u> |
|---|---------------------|------------|------------|----------------------|--------------|---------------------------------------|------------|------------|------|---------------|
| Male female 4 4.3 nnc (nc-nc) Female 2 2.8 nc (nc-nc) Female 1 1.5 nc (nc-nc) Female 3 2.1 nc (nc-nc) Brain and Other New-vow System Multiple Myelona Female 0 0.9 nc (nc-nc) Male 0 0.0 nc (nc-nc) Female 0 0.1 nc (nc-nc) Mon-Hodskin Lymphoms v v (nc-nc) (nc-nc) Female 0 0 1 nc (nc-nc) (nc-nc) Female 1 nc (nc-nc) (nc-nc) Female 1 nc (nc-nc) (nc-nc) (nc-nc) nc (nc-nc) nc (nc-nc) nc (nc-nc) nc nc< | Dladdor Urinani | <u>ODS</u> | <u>Exp</u> | SIK | 93 /0 CI | Malanama of Clrin | <u>ODS</u> | <u>Exp</u> | SIK | 93 % CI |
| Female 1 1.5 one (nc-nc) Female 3 2.1 one (nc-nc) Brain and Other Nerversystem Male 1 0.9 nc (nc-nc) Female 0 0.5 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 0 0.5 nc (nc-nc) Brail 0 0.1 nc (nc-nc) Male 0 2.4 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.7 nc (nc-nc) Female 1 0.7 nc (nc-nc) Pemale 1 0.7 nc (nc-nc) Female 1 0.7 nc (nc-nc) Pemale 1 1.0 (nc-nc) Female 1 0.5 nc (nc-nc) Pemale 4 1.2 nc (nc-nc) Female | | 4 | 4.2 | no | (no no) | | 2 | 2.0 | no | (no no) |
| Brain and Other New York Serial of the New York 0 (nc.nc) (nc.nc) Male (nc.nc) (nc.nc) Male (nc.nc) (nc.nc) 0 (nc.nc) (nc.nc) (nc.nc) (nc.nc) | | | | | | | | | | |
| Male Female 1 0.9 nc (nc-nc) Male Female 1 0.7 nc (nc-nc) Breast Mon-Hodgkin Lymphoms Bremale 0 0.1 nc (nc-nc) Female 21 0.15 133.1 (824-2035) Female 3 1.9 nc (nc-nc) Female 21 0.15 133.1 (824-2035) Female 3 1.9 nc (nc-nc) Female 21 0.15 133.1 (824-2035) Female 3 1.9 nc (nc-nc) Female 3 0.7 nc (nc-nc) Female 1 1.9 nc (nc-nc) Female 4 6.6 nc (nc-nc) Pemale 4 1.0 nc (nc-nc) Female 1 1.0 nc (nc-nc) Pemale 4 1.2 nc (nc-nc) Female 1 | | | | nc | (nc-nc) | | 3 | 2.1 | nc | (nc-nc) |
| Female 0 0.6 nc (nc-nc) Female 0 0.5 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.1 nc (nc-nc) Male 0 2.4 nc (nc-nc) Female 1 1.58 13.31 (82.4-203.5) Female 3 1.9 nc (nc-nc) Cevix Uteri " Call Cavity and Pharynx Male 1 0.7 nc (nc-nc) Female 1 1.9 nc (nc-nc) Female 1 0.7 nc (nc-nc) Ovary Temale 1 1.9 nc (nc-nc) Female 1 0.7 nc (nc-nc) Pemale 4 1.7 nc (nc-nc) Female 1 0.3 nc (nc-nc) Pemale 1 1.2 nc (nc-nc) Female 0 0.4 nc <td></td> <td></td> <td></td> <td></td> <td>, ,</td> <td></td> <td></td> <td>0.7</td> <td></td> <td>, ,</td> | | | | | , , | | | 0.7 | | , , |
| Mon-Hodgkin Lymphoma: Male Name 0 0.1 nc (nc.nc) Male Name 0 2.4 nc (nc.nc) Female Perwix 21 15.8 133.1 (82.4-203.6) Female 3 19 nc (nc.nc) Cervix Uri Female 1 0.7 nc (nc.nc) Pance Name 0 0.7 nc (nc.nc) Female Female 1 0.7 nc (nc.nc) Female 1 1 nc (nc.nc) Color Necture V Color Necture V 0 0 7 nc (nc.nc) Female 4 6.6 nc (nc.nc) Female 4 1.7 nc (nc.nc) Female 1 1.2 nc (nc.nc) Female 4 1.2 nc (nc.nc) Female 1 0 0 (nc.nc) Female 1 1 nc (nc.nc) | | | | | | | | | | |
| Male Female 0 0.1 nc (nc-nc) Male Female 0 2.4 nc (nc-nc) Cervix Uteri Female Pharyms Female 1 0.7 nc (nc-nc) Female Female 0 0.7 nc (nc-nc) Female 1 0.7 nc (nc-nc) Female Female 0 0.7 nc (nc-nc) Colon/Rectum Owary Male 4 6.6 nc (nc-nc) Female Female 4 1.7 nc (nc-nc) Female 8 5.5 14.63 (63.0-288.2) Female Female 4 1.7 nc (nc-nc) Female 8 5.5 14.63 (63.0-288.2) Female Female 4 1.7 nc (nc-nc) Female 8 1 1.2 nc (nc-nc) Female Female 4 1.2 nc (nc-nc) Female 0 1 1 nc (nc-nc) 1 nc (nc-nc) nc nc | | 0 | 0.6 | nc | (nc-nc) | | 0 | 0.5 | nc | (nc-nc) |
| Female 21 15.8 133.1 (82.4-203.5) Female 3 1,9 nc (nc.nc) Cervix Uteri Cervix Uteri Male 1 1,9 nc (nc.nc) Female 1 0,7 nc (nc.nc) Female 0 0,7 nc (nc.nc) Osany Osany <td></td> | | | | | | | | | | |
| Cervix Uteri Oral Cavity and Pharynx Cervix Uteri Image: Male 1 0.79 onc. (nc.nc) Female 1 0.79 nc. (nc.nc) Cnc.nc) Female 0 0.79 nc. (nc.nc) Male 4 0.70 nc. (nc.nc) Pancreas Female 4 0.71 nc. (nc.nc) Pancreas Pancreas Male 1 0.2 nc. (nc.nc) Female 4 1.7 nc. (nc.nc) Female 1 0.2 nc. (nc.nc) Female 4 1.3 nc. (nc.nc) (nc.nc) Female 1 0.3 nc. (nc.nc) Female 4 1.3 nc. (nc.nc) (nc.nc) Panters Male 0 0.3 nc. (nc.nc) Female 4 1.2 ac. (nc.nc) Male 0 0.3 nc. (nc.nc) Female 1 1.1 nc. (nc.nc) (nc.nc) Female </td <td></td> | | | | | | | | | | |
| Female | Female | 21 | 15.8 | 133.1 | (82.4-203.5) | | 3 | 1.9 | nc | (nc-nc) |
| Female 1 0.7 nc (nc-nc) Female 0 0.7 nc (nc-nc) Colon/Rectum Male 4 6.6 nc (nc-nc) Female 4 1.7 nc (nc-nc) Female 8 5.5 146.3 (63.0-288.2) Female 4 1.7 nc (nc-nc) Esophagus Pancreas 3 nc (nc-nc) Male 4 1.3 nc (nc-nc) female 1 1.8 2 (46.0-135.6) female 1 1.1 nc (nc-nc) female 1 1.1 nc (nc-nc) female 1 1.1 | Cervix Uteri | | | | | | | | | |
| Colon/Rectum Male 4 6.6 nc (nc-nc) Female 8 5.5 146.3 (63.0~288.2) Female 4 1.7 nc (nc-nc) Esophagus Pancreas Male 1 1.2 nc (nc-nc) Male 4 1.3 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.3 nc (nc-nc) Hodgkin Lymphome "Forstat 1 1.2 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.0 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Kidney and Renal Pelviv v 2 2 nc (nc-nc) Female 1 1 nc (nc-nc) Male 2 2.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) | | | | | | | | | nc | |
| Male 4 6.6 nc (nc-nc) Female 8 5.5 146.3 (63.0-288.2) Female 4 1.7 nc (nc-nc) Esophagus Pancreas Male 1 1.2 nc (nc-nc) Male 4 1.3 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoms Prostate Male 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Kidney and Renal Pelvis State State Male 2 2.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 1 0.8 nc (nc-nc) Male 0 | Female | 1 | 0.7 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| Female 8 5.5 146.3 (63.0-288.2) Female 4 1.7 nc (nc-nc) Esophagus Pancreas Male 1 1.2 nc (nc-nc) Male 4 1.3 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoma Prostate Male 0 0.4 nc (nc-nc) Male 15 82.2 82.2 (nc-nc) Female 0 0.3 nc (nc-nc) Male 1 1.1 nc (nc-nc) Male 2 2.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 1 0.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Female 1 0.8 nc (nc-nc) Male 1 0.7 nc < | Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Esophagus Pancreas Male 1 1.2 nc (nc-nc) Male 4 1.3 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoma Prostate Male 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.3 nc (nc-nc) Male 1 1.1 nc (nc-nc) Kidney and Renal Pelvis Stomach Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 0.1 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 1 0.8 nc (nc-nc) Male 1 0.7 nc (nc-nc) Leukemia 1 0.1 nc (n | Male | 4 | 6.6 | nc | (nc-nc) | | | | | |
| Male 1 1.2 nc (nc-nc) Male 4 1.3 nc (nc-nc) Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoma Prostate Male 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.3 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Kidney and Renal Pelvs Stomach Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 1 0.8 nc (nc-nc) Male 1 0.7 nc (nc-nc) Leukemia 1 0 1.4 nc (nc-nc) Female <td>Female</td> <td>8</td> <td>5.5</td> <td>146.3</td> <td>(63.0-288.2)</td> <td>Female</td> <td>4</td> <td>1.7</td> <td>nc</td> <td>(nc-nc)</td> | Female | 8 | 5.5 | 146.3 | (63.0-288.2) | Female | 4 | 1.7 | nc | (nc-nc) |
| Female 1 0.3 nc (nc-nc) Female 4 1.2 nc (nc-nc) Hodgkin Lymphoma Prostate Male 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.3 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Kidney and Renal Pelvis Stomach Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 1.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Larynx Testis Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Eukewia 1 0.7 nc (nc-nc) Eukewia 1 0.7 nc (nc-nc) </td <td>Esophagus</td> <td></td> <td></td> <td></td> <td></td> <td><u>Pancreas</u></td> <td></td> <td></td> <td></td> <td></td> | Esophagus | | | | | <u>Pancreas</u> | | | | |
| Hodgkin Lymphoma Prostate Male Nale 0 0 0.4 nc (nc-nc) Male Nale Nale 15 18.2 82.2 (46.0-135.6) Female 0 0 0.3 nc (nc-nc) Stomach Stomach Male Pemale Pelvis Stomach 1 1.1 nc (nc-nc) nc (nc-nc) Female Pemale 0 1 0.1 nc (nc-nc) Female Pemale 0 0.6 nc (nc-nc) Larynx Testis 3 nc (nc-nc) Male Nale Nale Nale Nale Nale Nale Nale N | Male | 1 | 1.2 | nc | (nc-nc) | Male | 4 | 1.3 | nc | (nc-nc) |
| Male Female 0 0.4 nc (nc-nc) Male 15 18.2 82.2 (46.0-135.6) Female 0 0.3 nc (nc-nc) Stomach Male Pelvis Stomach Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 1.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Larynx Testis Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Male 1 0.7 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, Nos Lung and Bronchus 1 nc (nc-nc) Female 3 3.4 nc (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) | Female | 4 | 1.2 | nc | (nc-nc) |
| Female 0 0.3 nc (nc-nc) | Hodgkin Lymphoma | <u>l</u> | | | | <u>Prostate</u> | | | | |
| Kidney and Renal Pelvis Stomach Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 1.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Larynx Testis Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Male 0 0.6 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Female 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) | Male | 15 | 18.2 | 82.2 | (46.0-135.6) |
| Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 1.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Male 0 0.6 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.4 nc (nc-nc) Female 1 0.7 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 < | Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| Male 2 2.2 nc (nc-nc) Male 1 1.1 nc (nc-nc) Female 1 1.2 nc (nc-nc) Female 0 0.6 nc (nc-nc) Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Male 0 0.6 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.4 nc (nc-nc) Female 1 0.7 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 < | Kidney and Renal Pe | elvis_ | | | | <u>Stomach</u> | | | | |
| Larynx Testis Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Thyroid Thyroid Thyroid Nale 0 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bit Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | Male | 2 | 2.2 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | Female | 1 | 1.2 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Male 1 0.8 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.2 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | Larynx | | | | | Testis | | | | |
| Female 0 0.2 nc (nc-nc) Leukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 3 3.4 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | | 1 | 0.8 | nc | (nc-nc) | · · · · · · · · · · · · · · · · · · · | 0 | 0.6 | nc | (nc-nc) |
| Eukemia Thyroid Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | | | | nc | | | | | | , , |
| Male 0 1.4 nc (nc-nc) Male 1 0.7 nc (nc-nc) Female 0 1.0 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | | | | | , | Thyroid | | | | |
| Female 0 1.0 nc (nc-nc) Female 2 1.9 nc (nc-nc) Liver and Intrahepatic Bile Ducts Male 2 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 0 1.3 nc (nc-nc) All Sites / Types | | 0 | 1.4 | nc | (nc-nc) | | 1 | 0.7 | nc | (nc-nc) |
| Liver and Intrahepatic Bile Ducts Male 2 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | | | | | | | | | | , , |
| Male 2 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | | | | | (, | | | | | (, |
| Female 0 0.3 nc (nc-nc) Female 3 3.4 nc (nc-nc) Lung and Bronchus All Sites / Types | • | | | nc | (nc-nc) | <u> </u> | | | | |
| <u>Lung and Bronchus</u> <u>All Sites / Types</u> | | | | | | Female | 3 | 3.4 | nc | (nc-nc) |
| | | | 0.0 | | (| | Ü | 0.1 | | (|
| 0 0.0 7.10 (10.1 100.2) Wall 01 01.0 01.7 (00.0 117.7) | - | | 8.5 | 94.5 | (40.7-186.2) | | 54 | 61.5 | 87 9 | (66.0-114.7) |
| Female 5 7.3 68.9 (22.2-160.8) Female 62 52.4 118.4 (90.8-151.8) | | | | | | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 0<u>bs</u> Obs Ехр SIR 95% CI Ехр SIR 95% CI Bladder, Urinary Melanoma of Skin 2.4 1 0 1.3 Male nc (nc-nc) Male nc (nc-nc) 0 Female 0.7 nc (nc-nc) Female 2 0.9 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 0.4 0 0.4 (nc-nc) Male nc (nc-nc) Male nc Female 0 0.3 Female 0 0.2 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.1 (nc-nc) Male 0 1.2 (nc-nc) nc nc Female 3 7.2 (nc-nc) Female 0 0.9 (nc-nc) nc nc Cervix Uteri Oral Cavity and Pharynx 2 0.8 (nc-nc) Male nc 0 0 0.3 Female 0.3 (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 2 3.5 nc (nc-nc) 5 2 0.8 Female 2.6 192.1 (61.9-448.4)**Female** (nc-nc) nc **Pancreas Esophagus** 0 0.6 1 0.7 Male nc (nc-nc) Male nc (nc-nc) 0 0 0.6 Female 0.1 nc (nc-nc) Female nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 6 9.2 65.5 (23.9-142.5)nc (nc-nc) Male Female 0 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 0 1.0 nc (nc-nc) Male 0 0.6 nc (nc-nc) Female 0 0.6 (nc-nc) Female 0 0.3 (nc-nc) nc nc Larynx **Testis** 0 0 0.2 0.4 Male (nc-nc) Male (nc-nc) nc nc 0 Female 0.1 (nc-nc) nc **Leukemia Thyroid** 0 0.7 0 0.3 Male nc (nc-nc) Male (nc-nc) nc Female 0 0.4 nc (nc-nc) Female 1 0.7 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 0.5 nc (nc-nc) Female 0 0.1 Female 2 nc (nc-nc) 1.6 nc (nc-nc) Lung and Bronchus All Sites / Types

• Obs = observed case count; Exp = expected case count;

4.5

3.5

Male

Female

1

4

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

(nc-nc)

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

nc

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Male

Female

15

20

48.4

82.9

31.0

24.1

(27.0-79.8)

(50.6-128.0)

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 0<u>bs</u> Obs SIR 95% CI SIR 95% CI Ехр Exp Bladder, Urinary Melanoma of Skin Male 3 1.9 0 1.1 nc (nc-nc) Male nc (nc-nc) 0 Female 0.6 nc (nc-nc) Female 0 0.8 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 0.3 1 0.3 (nc-nc) Male nc (nc-nc) Male nc Female 0 0.3 Female 0 0.2 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.1 (nc-nc) Male 1 1.0 (nc-nc) nc nc Female 5 6.1 82.2 (26.5-191.8)Female 2 8.0 (nc-nc) nc Cervix Uteri Oral Cavity and Pharynx 0 0.7 (nc-nc) Male nc Female 0 0.3 0 0.3 (nc-nc) Female (nc-nc) nc nc Colon / Rectum Ovary Male 0 2.8 nc (nc-nc) 0 **Female** 1 2.3 (nc-nc) **Female** 0.7 (nc-nc) nc nc **Esophagus Pancreas** 0 Male 1 0.5 0.6 nc (nc-nc) Male nc (nc-nc) 0 Female 0.1 (nc-nc) Female 0 0.5 nc (nc-nc) nc Hodgkin Lymphoma **Prostate** 0 0.1 4 7.2 Male (nc-nc) Male (nc-nc) nc nc Female 0 0.1 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 0 8.0 nc (nc-nc) Male 0 0.5 (nc-nc) nc Female 0 0.5 (nc-nc) Female 1 0.2 (nc-nc) nc nc Larynx **Testis** 0 0.3 0 0.2 Male (nc-nc) Male (nc-nc) nc nc 0 Female 0.1 (nc-nc) nc **Leukemia Thyroid** 0.6 0 0.3 Male 1 nc (nc-nc) Male (nc-nc) nc Female 2 0.4 nc (nc-nc) Female 0 0.7 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 0.4 nc (nc-nc) Female 0 0.1 Female 3 nc (nc-nc) 1.3 nc (nc-nc) Lung and Bronchus All Sites / Types Male 4 3.5 (nc-nc) Male 17 25.0 68.1 (39.7-109.1)nc Female 3 2.9 nc (nc-nc) Female 18 20.7 87.0 (51.5-137.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

| | | | | • | , with Standardized incidence R | | | | |
|---------------------|---------------|------------|------------|--|---------------------------------|------------|------------|-------|---------------|
| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | SIR | <u>95% CI</u> |
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 3 | 3.9 | nc | (nc-nc) | Male | 5 | 2.4 | 210.1 | (67.7-490.3) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 3 | 1.8 | nc | (nc-nc) |
| Brain and Other Ne | rvous Sys | | | | Multiple Myeloma | | | | |
| Male | 0 | 8.0 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphoma | <u>l</u> | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 18 | 13.5 | 133.8 | (79.3-211.5) | Female | 3 | 1.7 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 1 | 5.8 | nc | (nc-nc) | | | | | |
| Female | 9 | 4.9 | 184.3 | (84.1-349.9) | Female | 1 | 1.4 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 2 | 1.1 | nc | (nc-nc) |
| Hodgkin Lymphom | <u>a</u> | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 21 | 15.5 | 135.8 | (84.0-207.6) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| Kidney and Renal F | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 1 | 1.8 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 2 | 1.6 | nc | (nc-nc) |
| Liver and Intrahepa | itic Bile Du | ıcts | | | Uteri Corpus and Uterus | NOS | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 2 | 2.9 | nc | (nc-nc) |
| Lung and Bronchus | | | | , , | All Sites / Types | | | | . , |
| Male | - 3 | 7.5 | nc | (nc-nc) | Male | 51 | 52.9 | 96.4 | (71.8-126.7) |
| Female | 12 | 6.3 | 191.7 | (99.0-334.9) | Female | 60 | 45.2 | 132.6 | (101.2-170.7) |
| | | | | ,, | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs Ехр 95% CI Obs SIR 95% CI SIR Exp Bladder, Urinary Melanoma of Skin 52 39.9 130.2 (97.2-170.7) 15 23.6 63.6 (35.5-104.8)Male Male 13 Female 16.0 81.1 (43.1-138.6)Female 16 20.8 76.8 (43.9-124.7)**Brain and Other Nervous System** Multiple Myeloma 15 7.5 199.7 (111.7-329.4)5 6.2 81.1 Male Male (26.1-189.3)Female 5 6.5 76.5 (24.7-178.5) Female 1 4.9 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 1 1.1 (nc-nc) Male 18 20.9 86.0 (50.9-135.9)nc 149.9 Female 117 78.0 (64.5-93.5)Female 24 20.7 116.1 (74.4-172.8)Cervix Uteri Oral Cavity and Pharynx 15 106.2 14.1 (59.4-175.2)Male 7 6.7 105.1 9 7.5 120.5 Female (42.1-216.5)Female (55.0-228.8)Colon / Rectum Ovary Male 78 58.1 134.2 (106.1-167.5) **Female** 61 61.1 99.9 (76.4-128.3)**Female** 18 16.3 110.5 (65.5-174.6)**Esophagus Pancreas** 7 9.9 160.8 (91.9-261.2) 11.6 60.3 (24.2-124.3)Male 16 Male 2 Female Female 3.1 (nc-nc) 18 13.4 134.6 (79.8-212.8)nc Hodgkin Lymphoma **Prostate** 82.9 4 3.5 Male 123 148.4 (68.9-98.9)Male nc (nc-nc) Female 2 2.8 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 20 17.4 114.9 (70.2-177.5)Male 13 9.8 133.2 (70.9-227.8)Female 16 11.9 134.3 (76.7-218.2)Female 10 6.5 153.9 (73.7-283.0)Larynx **Testis** 3 6.1 6 6.3 95.4 Male (nc-nc) Male (34.8-207.7)nc 3 Female 1.8 (nc-nc) nc **Leukemia Thyroid** 11 84.6 3 5.5 Male 13.0 (42.2-151.4)Male (nc-nc) nc Female 8 11.0 72.8 (31.4-143.5)Female 20 18.1 110.3 (67.3-170.3)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 11 8.3 133.3 (66.4-238.5)Female 4 3.2 Female 19 59.5 (35.8-92.9)nc (nc-nc) 31.9 Lung and Bronchus All Sites / Types 120.4 101.9 (93.5-110.9)Male 90 74.7 (96.8-148.0) Male 535 524.9 Female 109 75.9 143.6 (117.9-173.2)Female 523 532.3 98.2 (90.0-107.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | , with Standardized moldene | Obs | <u>Ехр</u> | SIR | 95% CI |
|--------------------------|--------------|-------------|-------|--------------|-----------------------------|-----------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | |
| Male | 32 | 22.4 | 143.2 | (97.9-202.1) | Male | 15 | 12.4 | 121.0 | (67.7-199.6) |
| Female | 8 | 9.3 | 86.3 | (37.1-170.0) | Female | 8 | 10.5 | 76.4 | (32.9-150.6) |
| Brain and Other Ner | vous Sys | <u>tem</u> | | | Multiple Myeloma | | | | |
| Male | 3 | 3.7 | nc | (nc-nc) | Male | 6 | 3.4 | 176.5 | (64.5-384.2) |
| Female | 4 | 3.3 | nc | (nc-nc) | Female | 2 | 2.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 11 | 11.2 | 98.6 | (49.2-176.5) |
| Female | 78 | 79.6 | 98.0 | (77.4-122.2) | Female | 12 | 11.6 | 103.7 | (53.5-181.2) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 7 | 7.6 | 91.8 | (36.8-189.1) |
| Female | 2 | 3.1 | nc | (nc-nc) | Female | 3 | 4.1 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 26 | 32.2 | 8.08 | (52.8-118.4) | | | | | |
| Female | 23 | 36.3 | 63.3 | (40.1-95.0) | Female | 9 | 8.8 | 102.7 | (46.8-194.9) |
| Esophagus | | | | | <u>Pancreas</u> | | | | |
| Male | 8 | 5.5 | 146.3 | (63.0-288.2) | Male | 3 | 6.5 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 7 | 7.9 | 88.6 | (35.5-182.5) |
| Hodgkin Lymphoma | <u>l</u> | | | | <u>Prostate</u> | | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | Male | 111 | 80.2 | 138.4 | (113.9-166.7) |
| Female | 1 | 1.2 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 15 | 9.3 | 161.1 | (90.1-265.8) | Male | 8 | 5.5 | 146.7 | (63.2-289.2) |
| Female | 8 | 6.5 | 122.9 | (52.9-242.2) | Female | 4 | 4.0 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 4 | 3.3 | nc | (nc-nc) | Male | 5 | 2.4 | 212.7 | (68.6-496.5) |
| Female | 0 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 6.9 | 145.7 | (69.7-267.9) | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 4 | 6.1 | nc | (nc-nc) | Female | 5 | 8.2 | 61.3 | (19.7-142.9) |
| Liver and Intrahepat | ic Bile Du | <u>icts</u> | | | Uteri Corpus and Uteri | us, NOS | | | |
| Male | 2 | 4.4 | nc | (nc-nc) | | | | | |
| Female | 2 | 1.9 | nc | (nc-nc) | Female | 16 | 16.8 | 95.1 | (54.3-154.5) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 40 | 41.0 | 97.6 | (69.7-132.9) | Male | 327 | 283.8 | 115.2 | (103.1-128.4) |
| Female | 45 | 42.1 | 106.9 | (77.9-143.0) | Female | 266 | 291.2 | 91.3 | (80.7-103.0) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

| | <u>Obs</u> | <u>Exp</u> | Served and E7 | 95% CI | with Standardized incluen | Obs | Exp | SIR | 95% CI |
|--------------------|---------------|------------|---------------|----------------|---------------------------|-------------|----------|----------|-----------------|
| Bladder, Urinary | <u> </u> | =~k | <u> </u> | <u>7070 01</u> | Melanoma of Skin | <u> </u> | <u> </u> | <u> </u> | <u> 7070 0.</u> |
| Male | 115 | 102.8 | 111.9 | (92.3-134.3) | Male | 20 | 58.5 | 34.2 | (20.9-52.8) |
| Female | 48 | 45.1 | 106.4 | (78.4-141.1) | Female | 22 | 53.3 | 41.3 | (25.8-62.5) |
| Brain and Other N | | | | , | Multiple Myeloma | | | | , |
| Male | 16 | 18.5 | 86.3 | (49.3-140.2) | Male | 14 | 15.7 | 89.0 | (48.6-149.3) |
| Female | 20 | 17.2 | 116.6 | (71.2-180.0) | Female | 12 | 13.7 | 87.5 | (45.1-152.8) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymph | <u>noma</u> | | | |
| Male | 0 | 2.8 | nc | (nc-nc) | Male | 50 | 52.6 | 95.1 | (70.6-125.4) |
| Female | 332 | 389.2 | 85.3 | (76.4-95.0) | Female | 49 | 57.0 | 85.9 | (63.5-113.6) |
| Cervix Uteri | | | | | Oral Cavity and Pha | <u>rynx</u> | | | |
| | | | | | Male | 48 | 35.4 | 135.5 | (99.9-179.6) |
| Female | 28 | 16.2 | 172.6 | (114.7-249.5) | Female | 20 | 20.0 | 100.0 | (61.0-154.4) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 171 | 148.7 | 115.0 | (98.4-133.6) | | | | | |
| Female | 152 | 175.1 | 86.8 | (73.6-101.8) | Female | 44 | 43.1 | 102.1 | (74.2-137.1) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 26 | 25.2 | 103.0 | (67.3-150.9) | Male | 36 | 29.8 | 121.0 | (84.7-167.5) |
| Female | 5 | 8.9 | 56.2 | (18.1-131.2) | Female | 34 | 38.2 | 88.9 | (61.6-124.3) |
| Hodgkin Lymphon | <u>na</u> | | | | <u>Prostate</u> | | | | |
| Male | 5 | 8.3 | 60.5 | (19.5-141.1) | Male | 292 | 371.8 | 78.5 | (69.8-88.1) |
| Female | 8 | 7.1 | 112.0 | (48.2-220.7) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 48 | 43.5 | 110.4 | (81.4-146.4) | Male | 39 | 25.2 | 155.1 | (110.2-212.0) |
| Female | 34 | 32.1 | 105.9 | (73.3-148.0) | Female | 36 | 19.0 | 189.6 | (132.8-262.5) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 26 | 15.5 | 167.7 | (109.5-245.7) | Male | 5 | 13.8 | 36.1 | (11.6-84.3) |
| Female | 8 | 4.8 | 166.8 | (71.8-328.7) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 37 | 33.1 | 111.9 | (78.8-154.3) | Male | 6 | 13.0 | 46.3 | (16.9-100.7) |
| Female | 33 | 30.6 | 107.8 | (74.2-151.4) | Female | 44 | 43.4 | 101.4 | (73.6-136.1) |
| Liver and Intrahep | atic Bile D | | | | Uteri Corpus and Uter | erus, NOS | | | |
| Male | 31 | 20.7 | 149.6 | (101.7-212.4) | | | | | |
| Female | 12 | 9.1 | 131.7 | (68.0-230.1) | Female | 83 | 82.5 | 100.6 | (80.1-124.7) |
| Lung and Bronchu | | | | | All Sites / Types | | | | |
| Male | 258 | 189.5 | 136.1 | (120.0-153.8) | Male | 1370 | 1324.1 | 103.5 | (98.1-109.1) |
| Female | 165 | 207.4 | 79.6 | (67.9-92.7) | Female | 1309 | 1432.2 | 91.4 | (86.5-96.5) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | Will Standardized incluence | Obs | -2003 <u>Ехр</u> | SIR | 95% CI |
|--------------------|---------------|------------|----------|---|-----------------------------|-----------|---------------------|----------|----------------|
| Bladder, Urinary | <u> </u> | <u> </u> | <u> </u> | <u>7070 01</u> | Melanoma of Skin | <u> </u> | <u>-~F</u> | <u> </u> | <u>7070 01</u> |
| Male | 67 | 56.2 | 119.2 | (92.4-151.4) | Male | 52 | 29.5 | 176.0 | (131.4-230.8) |
| Female | 16 | 20.3 | 78.8 | (45.0-128.0) | Female | 27 | 22.7 | 118.9 | (78.3-173.0) |
| Brain and Other No | | | | (************************************** | Multiple Myeloma | | | | (1 1 1 1 7 |
| Male | 9 | 8.6 | 104.3 | (47.6-198.0) | Male | 15 | 8.4 | 177.5 | (99.3-292.9) |
| Female | 12 | 7.2 | 167.4 | (86.4-292.4) | Female | 8 | 6.2 | 129.7 | (55.8-255.6) |
| <u>Breast</u> | | | | | Non-Hodgkin Lymphor | <u>na</u> | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | Male | 32 | 26.8 | 119.6 | (81.8-168.9) |
| Female | 197 | 178.6 | 110.3 | (95.4-126.8) | Female | 29 | 25.0 | 115.8 | (77.5-166.3) |
| Cervix Uteri | | | | | Oral Cavity and Pharyr | <u>1X</u> | | | |
| | | | | | Male | 13 | 18.2 | 71.4 | (38.0-122.2) |
| Female | 5 | 6.8 | 73.9 | (23.8-172.5) | Female | 8 | 9.0 | 88.5 | (38.1-174.3) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 84 | 79.9 | 105.1 | (83.8-130.1) | | | | | |
| Female | 56 | 76.4 | 73.3 | (55.3-95.1) | Female | 18 | 19.5 | 92.2 | (54.6-145.7) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 9 | 13.6 | 66.2 | (30.2-125.7) | Male | 21 | 16.1 | 130.4 | (80.7-199.3) |
| Female | 1 | 4.0 | nc | (nc-nc) | Female | 21 | 16.9 | 124.1 | (76.8-189.8) |
| Hodgkin Lymphon | <u>1a</u> | | | | <u>Prostate</u> | | | | |
| Male | 2 | 3.1 | nc | (nc-nc) | Male | 237 | 205.6 | 115.3 | (101.1-130.9) |
| Female | 1 | 2.4 | nc | (nc-nc) | | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 28 | 22.7 | 123.1 | (81.8-177.9) | Male | 16 | 13.5 | 118.7 | (67.8-192.8) |
| Female | 16 | 14.6 | 109.5 | (62.6-177.9) | Female | 9 | 8.1 | 111.6 | (50.9-211.9) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 9 | 8.4 | 107.6 | (49.1-204.3) | Male | 9 | 4.4 | 206.6 | (94.3-392.1) |
| Female | 2 | 2.3 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 21 | 16.5 | 127.5 | (78.9-194.9) | Male | 6 | 5.8 | 103.6 | (37.8-225.5) |
| Female | 20 | 12.8 | 155.8 | (95.1-240.7) | Female | 10 | 17.6 | 56.9 | (27.2-104.6) |
| Liver and Intrahep | | | | | Uteri Corpus and Uteru | ıs, NOS | | | |
| Male | 2 | 10.9 | nc | (nc-nc) | | | | | |
| Female | 4 | 4.0 | nc | (nc-nc) | Female | 39 | 39.1 | 99.7 | (70.9-136.3) |
| Lung and Bronchu | | | | | All Sites / Types | | _ | | |
| Male - | 92 | 104.4 | 88.1 | (71.0-108.1) | Male | 774 | 705.9 | 109.6 | (102.1-117.7) |
| Female | 108 | 96.3 | 112.2 | (92.0-135.4) | Female | 664 | 641.3 | 103.5 | (95.8-111.7) |

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs SIR 95% CI Obs Ехр SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 45 59.5 39.8 113.0 (82.4-151.2) 14 23.5 (32.5-99.8)Male Male 15 Female 16.5 91.2 (51.0-150.4)Female 14 20.7 67.7 (37.0-113.6)**Brain and Other Nervous System** Multiple Myeloma 1 7.7 4 6.2 (nc-nc) Male nc (nc-nc) Male nc Female 8 6.7 119.1 (51.3-234.7)Female 3 5.0 (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 2 1.1 (nc-nc) Male 22 21.0 104.6 (65.5-158.4)Male nc Female 147 148.4 99.0 (83.7-116.4)Female 25 21.0 118.8 (76.9-175.4)Cervix Uteri Oral Cavity and Pharynx 18 125.8 14.3 (74.5-198.8)Male 7 108.8 8 7.6 105.9 Female 6.4 (43.6-224.3)Female (45.6-208.7)Colon / Rectum Ovary Male 53 58.1 91.1 (68.3-119.2)Female **Female** 62 63.7 97.3 (74.6-124.7)15 16.3 91.8 (51.4-151.5)**Esophagus Pancreas** 9 10.0 110.5 (55.1-197.8)11.6 77.6 (35.4-147.3)Male 11 Male Female 79.1 Female 4 3.2 nc (nc-nc) 11 13.9 (39.5-141.6)Hodgkin Lymphoma **Prostate** 4 3.6 134 146.9 91.2 Male nc (nc-nc) Male (76.4-108.1)Female 6 3.0 199.4 (72.8-434.1)Kidney and Renal Pelvis Stomach Male 18 17.4 103.4 (61.3-163.4)Male 10 9.8 102.4 (49.0-188.3)Female 14 11.9 117.2 (64.0-196.6)Female 7 6.9 101.5 (40.7-209.1)Larynx **Testis** 9 9 6.1 147.0 (67.1-279.1)6.2 146.2 Male Male (66.7-277.6)2 Female 1.8 nc (nc-nc)

Thyroid

2

10

26

479

495

Male

Female

Uteri Corpus and Uterus, NOS

Female

Male

Female

All Sites / Types

5.5

17.6

31.2

523.6

536.7

nc

56.7

83.3

91.5

92.2

(nc-nc)

(27.2-104.3)

(54.4-122.0)

(83.5-100.1)

(84.3-100.7)

• Obs = observed case count; Exp = expected case count;

13.2

11.6

8.3

3.3

74.1

75.9

Leukemia

Male

Male

Male

Female

Female

Lung and Bronchus

Liver and Intrahepatic Bile Ducts

Female

8

12

11

62

52

3

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

60.4

103.6

131.9

nc

83.6

68.5

(26.0-119.1)

(53.5-181.0)

(65.8-236.1)

(64.1-107.2)

(51.2-89.9)

(nc-nc)

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

| | Obs | <u>Exp</u> | erved and Exp SIR | 95% CI | with Standardized incluence Ka | Obs | <u>Ехр</u> | SIR | 95% CI |
|-----------------------|--------------|------------|----------------------|----------------|--------------------------------|------------|------------|------------|----------------|
| Bladder, Urinary | <u> </u> | LAP | <u>ont</u> | <u>7570 01</u> | Melanoma of Skin | <u> </u> | LAP | <u>ont</u> | <u>7570 GI</u> |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 0.2 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Brain and Other Ner | | | | (110 110) | Multiple Myeloma | • | | | (112 112) |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | , | Non-Hodgkin Lymphoma | | | | , , |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 5 | 2.6 | 192.4 | (62.0-449.1) | Female | 0 | 0.3 | nc | (nc-nc) |
| Cervix Uteri | | | | | Oral Cavity and Pharynx | | | | |
| | | | | | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Hodgkin Lymphoma | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Liver and Intrahepati | ic Bile Du | | | | Uteri Corpus and Uterus, | <u>NOS</u> | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 3 | 1.5 | nc | (nc-nc) | Male | 12 | 11.0 | 108.7 | (56.1-189.8) |
| Female | 3 | 1.2 | nc | (nc-nc) | Female | 12 | 8.7 | 137.6 | (71.0-240.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

| | <u>Obs</u> | <u>Ехр</u> | SIR | 95% CI | with Standardized incluence | Obs | <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|------------|-------|---------------|-------------------------------------|-----------|------------|-------|---------------|
| Bladder, Urinary | | | | | Melanoma of Skin | | | | <u> </u> |
| Male | 13 | 16.2 | 80.5 | (42.8-137.6) | Male | 19 | 10.3 | 184.1 | (110.8-287.6) |
| Female | 6 | 6.0 | 99.6 | (36.4-216.7) | Female | 11 | 8.6 | 127.5 | (63.6-228.2) |
| Brain and Other Ner | vous Sys | | | , | Multiple Myeloma | | | | , |
| Male | 3 | 3.4 | nc | (nc-nc) | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) | Female | 3 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | Non-Hodgkin Lympho | <u>ma</u> | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 10 | 9.0 | 111.0 | (53.1-204.2) |
| Female | 87 | 64.1 | 135.6 | (108.6-167.3) | Female | 9 | 8.0 | 113.1 | (51.6-214.7) |
| Cervix Uteri | | | | | Oral Cavity and Phary | <u>1X</u> | | | |
| | | | | | Male | 5 | 6.8 | 74.0 | (23.9-172.8) |
| Female | 2 | 2.9 | nc | (nc-nc) | Female | 3 | 3.0 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 37 | 24.4 | 151.3 | (106.5-208.6) | | | | | |
| Female | 32 | 22.6 | 141.3 | (96.7-199.5) | Female | 8 | 6.8 | 117.9 | (50.8-232.4) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 5 | 4.4 | 114.3 | (36.8-266.8) | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 7 | 4.9 | 141.8 | (56.8-292.1) |
| Hodgkin Lymphoma | 1 | | | | <u>Prostate</u> | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 63 | 66.6 | 94.6 | (72.7-121.0) |
| Female | 1 | 1.1 | nc | (nc-nc) | | | | | |
| Kidney and Renal P | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 12 | 7.9 | 151.7 | (78.3-265.1) | Male | 5 | 4.0 | 125.6 | (40.5-293.2) |
| Female | 3 | 4.8 | nc | (nc-nc) | Female | 3 | 2.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 2.8 | nc | (nc-nc) | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 3 | 8.0 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 7 | 5.5 | 127.4 | (51.0-262.6) | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 11 | 4.2 | 259.4 | (129.3-464.2) | Female | 5 | 7.9 | 63.3 | (20.4-147.7) |
| Liver and Intrahepat | ic Bile Du | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 3.8 | nc | (nc-nc) | | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 9 | 13.8 | 65.2 | (29.8-123.8) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 22 | 31.4 | 70.1 | (43.9-106.1) | Male | 243 | 226.8 | 107.2 | (94.1-121.5) |
| Female | 44 | 29.5 | 149.1 | (108.3-200.2) | Female | 262 | 214.3 | 122.2 | (107.9-138.0) |

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005 Obs SIR 95% CI Obs Ехр SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 52 78.1 66.6 (58.3-102.5)39 41.3 94.4 (67.1-129.1)Male Male 25 Female 26.0 96.3 (62.3-142.1)Female 40 35.8 111.7 (79.8-152.2)**Brain and Other Nervous System** Multiple Myeloma 10 75.7 (36.2-139.3)10.5 104.4 Male 13.2 Male 11 (52.0-186.7)Female 9 11.1 80.9 (36.9-153.6)Female 9 7.9 114.2 (52.1-216.8) Non-Hodgkin Lymphoma **Breast** 1 1.9 (nc-nc) Male 44 36.2 121.4 (88.2-163.0) Male nc Female 270 255.3 105.8 (93.5-119.2)Female 36 33.9 106.1 (74.3-146.9)Cervix Uteri Oral Cavity and Pharynx 22 25.6 86.0 (53.9-130.2)Male 136.9 20 12.5 159.6 Female 16 11.7 (78.2-222.3)Female (97.5-246.5)Colon / Rectum Ovary Male 98.9 113.3 (93.3-136.3)112 Female **Female** 110 100.2 109.8 (90.3-132.4)23 27.5 83.5 (52.9-125.3)**Esophagus Pancreas** 13 17.2 75.7 (40.3-129.4)13 19.7 66.0 (35.1-113.0)Male Male 5 98.7 Female Female 5.1 (31.8-230.3)27 21.7 124.4 (81.9-181.0)**Prostate** Hodgkin Lymphoma (56.5-258.4) 8 131.1 228 257.4 88.6 Male 6.1 Male (77.5-100.9)Female 2 4.9 (nc-nc) nc Kidney and Renal Pelvis Stomach Male 30 30.6 98.1 (66.2-140.1)Male 14 16.4 85.3 (46.6-143.2)Female 17 19.6 86.6 (50.4-138.6)Female 9 10.7 84.1 (38.4-159.7)Larynx **Testis** 9 7 10.7 83.8 (38.2-159.1)11.1 63.0 Male Male (25.3-129.9)Female 4 3.0 (nc-nc) nc **Leukemia Thyroid** 25 10.0 139.8 Male 22.2 112.6 (72.8-166.2)Male 14 (76.4-234.6)(79.4-188.0) Female 23 18.4 125.3 Female 39 32.2 121.2 (86.2-165.8) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 16 14.6 109.2 (62.4-177.4)Female 5 5.3 93.9 (30.2-219.0)Female 59 54.2 108.9 (82.9-140.5)**Lung and Bronchus** All Sites / Types 81.3 901.5 92.0 Male 102 125.5 (66.3-98.7)Male 829 (85.8-98.4)Female 115 122.0 94.3 (77.8-113.2)Female 924 888.7 104.0 (97.4-110.9)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

| | <u>Obs</u> | <u>Ехр</u> | Served and Ex | 95% CI | Willi Standardized incluence | Obs | -2003 <u>Ехр</u> | SIR | 95% CI |
|----------------------|--------------|-------------|---------------|----------------|------------------------------|------------------|---------------------|------------|-----------------|
| Bladder, Urinary | <u> </u> | LAP | <u>onv</u> | <u>7570 01</u> | Melanoma of Skin | 003 | LAP | <u>ont</u> | <u> 70 % 61</u> |
| Male | 27 | 21.5 | 125.3 | (82.6-182.4) | Male | 17 | 15.2 | 111.6 | (65.0-178.7) |
| Female | 8 | 8.1 | 99.1 | (42.7-195.3) | Female | 16 | 13.6 | 118.1 | (67.4-191.7) |
| Brain and Other Ner | | | 77 | (12.7 170.0) | Multiple Myeloma | 10 | 10.0 | 110.1 | (07.1 171.7) |
| Male | 9 | 5.4 | 166.3 | (75.9-315.7) | Male | 9 | 3.6 | 252.0 | (115.0-478.4) |
| Female | 1 | 4.4 | nc | (nc-nc) | Female | 4 | 2.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | (/ | Non-Hodgkin Lymphor | | | | () |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 6 | 13.1 | 45.7 | (16.7-99.4) |
| Female | 91 | 94.0 | 96.8 | (77.9-118.8) | Female | 15 | 11.2 | 133.5 | (74.7-220.2) |
| Cervix Uteri | | | | , , | Oral Cavity and Pharyr | | | | , , |
| | | | | | Male | 5 | 9.6 | 52.1 | (16.8-121.5) |
| Female | 4 | 4.9 | nc | (nc-nc) | Female | 4 | 4.3 | nc | (nc-nc) |
| Colon / Rectum | | | | | <u>Ovary</u> | | | | |
| Male | 27 | 33.4 | 80.9 | (53.3-117.7) | | | | | |
| Female | 27 | 30.9 | 87.4 | (57.6-127.2) | Female | 18 | 9.8 | 183.7 | (108.8-290.3) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 2 | 5.9 | nc | (nc-nc) | Male | 6 | 6.6 | 91.2 | (33.3-198.5) |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 3 | 6.6 | nc | (nc-nc) |
| Hodgkin Lymphoma | <u>1</u> | | | | <u>Prostate</u> | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | Male | 110 | 87.6 | 125.6 | (103.2-151.3) |
| Female | 3 | 1.9 | nc | (nc-nc) | | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | | <u>Stomach</u> | | | | |
| Male | 11 | 11.2 | 98.0 | (48.8-175.3) | Male | 2 | 5.4 | nc | (nc-nc) |
| Female | 2 | 6.7 | nc | (nc-nc) | Female | 2 | 3.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 3.7 | nc | (nc-nc) | Male | 5 | 4.8 | 105.1 | (33.9-245.2) |
| Female | 0 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 8.2 | nc | (nc-nc) | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 5 | 6.5 | 77.3 | (24.9-180.4) | Female | 12 | 13.6 | 88.4 | (45.6-154.4) |
| Liver and Intrahepat | tic Bile Du | <u>ıcts</u> | | | Uteri Corpus and Uteru | <u>ıs, NOS</u> | | | |
| Male | 3 | 5.4 | nc | (nc-nc) | | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | Female | 17 | 19.3 | 88.0 | (51.3-141.0) |
| Lung and Bronchus | | | | | All Sites / Types | | | | |
| Male | 53 | 41.6 | 127.4 | (95.4-166.7) | Male | 322 | 312.2 | 103.1 | (92.2-115.1) |
| Female | 28 | 39.3 | 71.2 | (47.3-102.8) | Female | 292 | 307.6 | 94.9 | (84.3-106.5) |

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;